



















































































A	 major	 therapeutic	 challenge	 is	 the	 increasing	 incidence	 of	 chronic	 disorders.	
The	persistent	 impairment	 or	 loss	 of	 tissue	 function	 requires	 constitutive	 on‐demand	
drug	availability	optimally	achieved	by	a	drug	delivery	system	ideally	directly	connected	
to	the	blood	circulation	of	the	patient.	However,	despite	the	efforts	and	achievements	in	





The	ability	 to	decellularize	segments	of	 the	rat	 intestine	while	preserving	 the	ECM	for	
subsequent	 reendothelialization	 was	 proven.	 The	 reestablishment	 of	 a	 functional	
arteriovenous	perfusion	circuit	enabled	the	supply	of	co‐cultured	cells	capable	to	replace	


















werdende	 therapeutische	 Herausforderung	 dar.	 Der	 anhaltende	 Funktionsverlust	 von	
Geweben	 erfordert	 die	 bedarfsgerechte	 Verfügbarkeit	 von	 Wirkstoffen,	 deren	
kontinuierliche	 Bereitstellung	 und	 Verteilung	 über	 die	 Blutzirkulation	 von	
implantierbaren	 Pharmakotherapie‐Produkten	 gelöst	 werden	 kann.	 Trotz	 der	
Fortschritte	 und	 Erfolge	 mit	 Zelltherapien	 sowie	 der	 Nachbildung	 der	 Zell‐eigenen	
Nischen	 konnten	 bisher	 noch	 keine	 funktionellen	 Gewebe	 für	 die	 medizinische	
Anwendbarkeit	hergestellt	werden.		
Diese	 Studie	 zeigt	 die	 Möglichkeit	 zur	 Herstellung	 einer	 vaskularisierten	 Plattform‐
Technologie	 um	 die	 Beschränkung	 der	 Nährstoff‐Versorgung	 zu	 überwinden	 für	 die	
Entwicklung	 von	 Transplantaten	 für	 die	 klinische	 Anwendung	 und	 deren	 sofortige	
Anastomose	an	die	Blutzirkulation.		
Die	Möglichkeit	Rattendarmsegmente	zu	dezellularisieren,	die	Extrazellulärmatrix	und	
das	 interne	 Gefäßsystem	 dabei	 jedoch	 zu	 erhalten	 um	 diese	 Strukturen	
wiederzubesiedeln	 wurde	 bewiesen.	 Das	 Wiederherstellen	 des	 funktionellen	
arteriovenösen	 Perfusionskreislaufs	 ermöglichte	 die	 Versorgung	 von	 Ko‐kultivierten	
Zellen	um	damit	funktionalen	Gewebeersatz	bzw.	‐modelle	aufzubauen	oder	als	Medizin‐
Produkt	 Einsatz	 zu	 finden.	 In	 vitro‐Studien	 zeigten	 eindrucksvoll	 Reife	 und	
Anwendbarkeit	 des	 hier	 entwickelten	 miniaturisierten,	 biologischen,	 vaskularisierten	
Scaffold	 (mBioVaSc‐TERM®).	Während	 in	 in	 vivo‐Studien	 zunächst	 vielversprechende	
Ergebnisse	 erzielt	wurden,	 zeigten	 Langzeit	 Implantationen	die	 aktuellen	Grenzen	 zur	



































































































































































































































































































Figure	 13.	 Liver‐like	 organoid	 implementation	 in	 the	 reendothelialized	 mBioVaSc‐
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During	 organogenesis,	 tissue	 environment	 is	 highly	 fluctuating	 due	 to	 continuous	 and	
extensive	extracellular	matrix	(ECM)	deposition,	degradation,	and	structural	organization	
as	well	as	cellular	proliferation,	migration,	and	differentiation1.		
For	 tissue‐specific	 function,	 ECM‐architecture	 and	 cellular	 homeostasis	 are	 critical3.	
However,	tissue	homeostasis	is	hardly	static	but	a	dynamic	reciprocity	between	cells	and	
ECM.	 The	 bidirectional	 interactions	 result	 in	 continuous	 ECM	 remodeling	 eliciting	
mechanical	 forces	 and	 biochemical	 mediators	 bound	 to	 the	 matrix	 triggering	 cellular	
responses	affecting	cell‐signaling	and	ECM	architecture4	by	secretion	of	ECM	components	
or	ECM‐degrading	enzymes5.		
The	 main	 classes	 of	 ECM	 macromolecules	 are	 proteoglycans	 and	 fibrous	 proteins.	
Proteoglycans	 mainly	 constitute	 hydrated	 gels	 depicting	 functional	 properties	 in	
hydration	 and	 buffering	 of	 mechanical	 force6.	 The	 major	 fibrous	 ECM	 proteins	 are	




deposition	 as	 well	 as	 cellular	 proliferation,	 differentiation,	 and	 ECM	 remodeling	 is	
unbalanced8.	During	wound	repair	homeostasis	is	gradually	recovered.	Regeneration	is	
usually	 orchestrated	 by	 a	 sequence	 of	 cytokines	 recruiting	 cells	 for	matrix	 formation,	
immunocompetent	 cells,	 tissue‐specific	 cells	 repopulating	 the	 newly	 formed	 tissue,	 as	
well	as	neovascularization9.	If	this	process	is	impaired	scar	formation	replaces	functional	









For	 replacement	of	an	endocrine	 function,	 it	 is	not	necessarily	 required	 to	 restore	 the	
whole	organ	but	only	the	respective	cells	or	their	secretome.		
The	cellular	secretory	function	can	be	substituted	and/or	regeneration	can	be	stimulated	
by	drug	delivery.	 The	disadvantage	 of	 classical	 pharmacological	 treatment	 is	 that	 it	 is	
usually	manually	applied	and	has	to	be	strictly	surveyed	as,	in	contrast,	endocrine	cells	
have	an	intrinsic	feedback	mechanism	regulating	the	secretion10.		
Furthermore,	 technical	 devices	 for	 drug	 delivery	 get	 increasingly	 applied11.	 Typically	
equipped	with	a	sensor	to	measure	e.g.	blood	glucose	level	and	a	pumping	device	loaded	
with	the	respective	compounds.	These	devices	are	commonly	either	externally	attached	
to	 the	 patient	 with	 a	 needle	 penetrating	 the	 skin	 or	 implanted	 subcutaneously.	 The	
problem	 for	 the	 implanted	 device	 besides	 encapsulation	 is	 the	 repeated	 surgical	
intervention	 when	 reloading	 the	 compounds.	 The	 external	 devices	 bear	 the	 risk	 of	
infection	due	to	the	needle	permanently	piercing	the	skin.		
An	 alternative	 is	 the	 transplantation	 of	 the	 respective	 cells/organoids	 or	 organs.	
However,	 facing	 drawbacks	 as	 donor	 compatibility	 and	 availability	 as	 well	 as	
immunosuppression12	in	addition	to	the	need	for	a	suitable	implantation	site	to	ensure	





mechanisms	 to	 ensure	 an	 intrinsic	 regulation	 for	 secretion.	 An	 alternative	 source	 for	
















being	 developed	 to	 alleviate	 healthcare	 problems	 related	 to	 the	 diseases	 of	 cellular	
deficiency,	including	loss	of	tissue/organ	functionality.	Tissues	and	organs	are	damaged	
by	disease	(acute	and	chronic),	trauma,	or	congenital	defects.	The	aim	is	to	support	the	
innate	 healing	 capabilities	 to	 recover	 tissues	 or	 to	 replace	 them	by	 in	 vitro	 generated	
grafts	(Fig.	1).		
While	the	current	definitions	of	TE	and	RM	were	determined	in	the	late	twentieth	century,	
the	basic	principles	 and	 ideas	date	back	more	 than	10,000	years18	 ago.	 10,000	before	
Christ	(BC)	the	principles	of	RM	have	been	applied	using	linen,	gut,	or	heads	of	large	biting	












































Critical‐size‐defects	 or	 loss	 of	 functions	of	 an	organ	 cannot	be	 compensated	naturally,	
thus,	for	reconstruction,	replacement	is	the	only	viable	treatment	option.	Approaches	in	
TE	combine	living	cells	and/or	growth	factors	with	materials	providing	an	appropriate	
microenvironment	 for	cells	 to	pursue	 their	native	 function.	Thereby,	 the	generation	of	
tissue	substitutes	providing	the	required	structures	and	components	enable	to	replace	or	
to	 stimulate	 the	 innate	 regenerative	 capabilities	 and	 restore	 the	 original	 tissue.	
Consequently,	when	generating	tissues	 in	vitro,	 it	 is	critical	 to	provide	an	environment	






non‐toxic,	 non‐immunogenic,	 non‐carcinogenic,	 nor	 dislocate	 or	 erode	 over	 time	 but	
integrate	into	the	adjacent	tissues32.		
Synthetic	 biomaterials	 used	 in	 TE	 are	 mainly	 polymers33,34,	 of	 which	 many	 have	
regulatory	approval	for	medical	application.	Manifold	other	materials	and	technologies,	
e.g.	 structured	 macroporous	 hydrogels35,	 electrospinning36,37,	 and	 bioprinting38,39	
emerged	within	the	last	years	to	generate	scaffolds	for	TERM.	During	chemical	synthesis,	
the	 material	 properties	 can	 be	 customized	 upon	 the	 aggregation	 state,	 injectability,	




immunogenicity	 upon	 implantation,	 especially	 in	 combination	 with	 allogenic	 or	






The	 most	 recently	 ascending	 natural	 scaffolds	 are	 decellularized	 tissue	 matrices.	
By	removing	 the	 tissue’s	 cells	 and	 remnants	 thereof,	 immunogenic	 reactions	 are	
avoided48	 while	 preservation	 of	 the	 natural	 ECM	 in	 structure,	 composition,	 and	
mechanical	 integrity	 enables	 the	 generation	 of	 a	 native‐like	 cellular	 environment	 for	
tissue	 generation	 and	 regeneration49.	 Therefore,	 the	 cellular	 phenotype	 can	 be	
maintained	and	cell	attachment,	motility,	and	differentiation50	is	facilitated.	Furthermore,	
its	 biological	 nature	 assures	 to	 be	 non‐toxic	 and	 biocompatible51.	 To	 restore	 tissue	
functionality,	the	scaffold	is	ideally	reseeded	with	autologous	cells.	Tissue	maturation	is	









Tissue	 functionality	 mostly	 requires	 specialized	 cell	 types,	 often	 a	 distinct	 spatial	







Primary	 cells	 are	 freshly	 isolated	 from	 tissue	 and	 therefore	 closely	 reflect	 the	natural	
cellular	 behavior	 and	 function.	 In	 contrast	 to	 cell	 lines,	 primary	 cells	 should	 only	 be	















Since	 iPSCs	 were	 first	 described	 in	 2006	 when	 differentiated	 adult	 cells	 were	
reprogrammed	 to	 a	pluripotent	embryonic‐like	 state	with	 the	 capacity	 to	differentiate	
into	 cells	 of	 all	 embryonic	 lineages64	 it	 was	 promised	 to	 be	 able	 to	 unlock	 hidden	
regenerative	potential	of	organs	similar	to	fish,	amphibians,	and	reptiles65.	Pluripotency	
describes	 the	 capacity	 of	 a	 stem	 cell	 to	 differentiate	 in	 any	 of	 the	 three	 germ	 layers:	
endoderm	 –	 developing	 e.g.	 the	 gastrointestinal	 tract	 and	 the	 lungs;	 mesoderm	 –	
developing	e.g.	muscle,	bone,	and	blood;	and	ectoderm	–	developing	e.g.	epidermal	tissues	
and	the	nervous	system66.	However,	most	applications	of	stem	cells	in	RM	are	inefficient	
and	 the	 anticipated	 hopes	 to	 cure	 degenerative	 diseases	 were	 not	 achieved,	 yet.	







Solid	 or	 nonporous	 prosthetic	materials	 failed	 in	 clinical	 application	 due	 to	 infection,	
dislodgement,	 migration,	 extrusion,	 and	 stenosis,	 as	 well	 as	 non‐re‐epithelialization,	
precluding	long	term	incorporation32.		
Employing	tracheal	allografts	instead	of	synthetic	windpipes	still	caused	immunological	






constitution71.	 Animal	 studies	 demonstrated	 the	 reduced	 immunogenic	 rejection	 after	
cryopreservation72,73	but	elicited	ischemia	in	the	grafts74,75.		
The	 final	 success	 to	 generate	 a	 functional	 replacement	 was	 achieved	 employing	 a	
decellularized	 matrix	 for	 tracheal	 reconstruction76.	 A	 decellularized	 porcine	 jejunal	
segment	 was	 reseeded	 with	 autologous	 costal	 chondrocytes,	 smooth	 muscle	 cells,	
respiratory	 epithelium,	 and	 endothelial	 progenitor	 cells.	 Bioreactor	 technology	 was	
employed	 for	 cellular,	 and	 consequently,	 tissue	 maturation	 by	 applying	 physiological	
stimuli	to	emerge	into	a	multi	cell	layered	in	vitro	vascularized	bioartificial	scaffold	with	
tracheal	functional	elements	including	respiratory	epithelium	cilial	movement77.		
The	 fails	 of	 cell‐free	 scaffolds	and	 the	 clinical	 success	of	 the	multi	 cellular	biologically	







tissue	 is	 due	 to	 the	 fact	 of	 proper	 nutrition	 while	 orchestration	 of	 homotypic	 and	
heterotypic	cell‐cell	interactions	in	a	spatially	controlled	micrometer	scaled	environment.	
The	 vascular	 network	 provides	 the	 infrastructure	 to	 supply	 the	 cells	 the	 required	
nutrients	and	oxygen	but	also	enables	the	metabolic	exchange	of	factors,	substrates	and	
products	and	maintains	the	water	and	protein	balance	between	intra‐	and	extravascular	













signals	 for	 patterning	 and	 organogenesis	 are	 provided	 by	 vasculogenic	 ECs80.	 Before	
further	maturation	of	the	vascular	network,	arteries	and	veins	composed	solely	of	ECs	are	
morphologically	 not	 discriminable,	 but	 on	molecular	 level	 the	 angioblasts	 are	 already	







existing	 vessels.	 During	 angiogenesis,	 the	 cells	 reorganize	 their	 vessel	 structure	 by	
migration	and	proliferation	forming	and	stabilizing	new	vascular	lumen84.	Major	trigger	
for	 vascular	 sprouting	 are	mechanical	 stimuli	 such	 as	 changes	 in	 blood	 flow,	 velocity,	
hydrostatic	pressure,	and	resistance	in	the	vascular	bed85.		
Besides	 endothelial	 cells	 composing	 the	 inner	 surface	 of	 blood	 and	 lymphatic	 vessels,	















Arterioles	 and	 venules	 are	 additionally	 covered	 by	 a	 layer	 of	 smooth	 muscle	 cells	 (SMCs).	
Artery	and	vein	depict	the	largest	vessels	in	terms	of	lumen	diameter	and	wall	thickness,	typically	









exchange	 of	 nutrients,	 oxygen,	 and	 waste	 products	 from	 the	 bloodstream66.	 Thereby,	
the	viability	of	cells	and	tissues	is	maintained,	furthermore,	making	regeneration	possible.		
Tissue‐engineered	 dense	 complex	 3D	 structures	 quickly	 exceed	 the	 nutrient	 diffusion	
limit,	thereby	becoming	inadequately	supplied,	ultimately	leading	to	necrosis88.	Without	








Besides	 the	 indispensability	of	 vascular	 structures	when	attempting	 to	generate	 living	
thick	tissues	 in	vitro,	 the	 lack	of	vascularization	also	 impedes	the	graft	 integration	and	







nutrition.	 Subsequently,	 various	 vascularization	 strategies	 arose	 approaching	 the	 task	
with	diverse	methods	such	as	scaffold	functionalization,	microfluidic	systems,	cell‐based	
techniques,	modular	assembly,	and	in	vivo	systems91.		
Scaffold	 functionalization	 comprised	 either	 various	 structural	 methods	 of	 increasing	
scaffold	porosity	up	to	the	formation	of	channels	to	form	perfusable	elements	within	the	




to	 establish	 a	 pre‐vascularization	 of	 a	 construct	 in	 order	 to	 provide	 a	 functional	
vasculature95.	The	degrees	of	pre‐vascularization	vary	from	in	vitro	establishment	before	
implantation96	to	in	vivo	self‐assembly	of	vascular	structures97.	Furthermore,	co‐cultures	
of	ECs	and	a	 combination	of	 tissue‐specific	 cell	 types,	 enable	 to	 establish	vascularized	
tissues98.	 The	 integration	 of	 ECs	 is	 achieved	 either	 as	 multicellular	 spheroids99,100	 or	
simple	 loose	mixing	of	 the	cells	 in	 the	scaffold101.	ECs,	especially	 in	spheroidal	culture,	
produce	 capillary‐like	 sprouts,	 increased	 in	 presence	 of	 angiogenic	 factors102	 and	
fibroblast	co‐culture103.	This	characteristic	is	utilized	for	scaffold	pre‐vascularization.		
An	 in	 vivo	 approach	 is	 the	 formation	 of	 an	 arteriovenous	 loop	with	 a	 host	 vessel	 and	
subsequent	embedding	in	a	tissue	chamber.	The	ECM	in	between	the	shunt	loop	within	








vascularized	 functional	 tissue	 up	 to	 a	 thickness	 of	 2	 mm106.	 Bigger	 more	 complex	
3D	tissues	might	be	generated	in	large	animal	models107.	However,	for	the	generation	of	
large	tissues	by	this	loop‐approach,	the	formation	of	vascularization	in	between	the	loop	
needs	 to	 be	 promoted	 in	 vitro	 by	 prevascularization	 or	 biochemical	 scaffold	
modification108.	However,	human	application	of	this	method	is	critical	as	it	either	requires	
repeated	 surgical	 interventions	 until	 full	 autologous	 graft	 vascularization	 or	 if	
vascularized	 in	 an	 animal	 model	 the	 graft	 will	 be	 xenograft	 requiring	
immunosuppression.	
Approaching	the	connection	between	scaffold	vascularization	and	host	circulation,	it	was	
demonstrated	 that	 pre‐vascularization	 of	 scaffolds	 accelerated	 the	 adhesion	 of	 the	
vascular	 networks109.	 The	 thereby	 created	 vascular	 pedicles	 for	 engineered	 tissues	
facilitated	 subsequent	 transplantation	 and	 thereby	 integration	 into	 the	 implantation	
site110,	 however	 requires	 multiple	 surgeries.	 Regarding	 clinical	 applicability,	 most	
approaches	 for	 graft	 vascularization	 are	 still	 only	 viable	 for	 small	 tissues	 as	 vascular	
ingrowth	 or	 self‐assembly	 in	 a	 dense	 tissue	 takes	 too	 long	 until	 full	 functional	







Gathering	 the	mentioned	 properties	 and	 concerns,	 an	 ideal	 scaffold	 should	 provide	 a	
microenvironment	for	3D	tissue‐like	cell	culture	with	an	embedded	vascular	network	that	
can	 be	 anastomosed	 to	 the	 blood	 circulation	 of	 a	 patient	 when	 considered	 for	
transplantation.	 The	 so	 far	 most	 promising	 engineered	 tissue	 combining	 the	 before	
mentioned	advantages	in	one	tissue	graft	was	the	BioVaSc‐TERM®.	The	BioVaSc‐TERM®	







of	 all	 vessel	 structures	 was	 highly	 critical.	 Also	 the	 decellularization	 protocol	 was	
established	to	preserve	the	vasculature.	The	subsequently	established	acellular	luminal	
intestinal	 structure	 served	 as	 a	 scaffold	 for	 3D	 cell	 culture	with	 a	 preserved	 vascular	
network.	Once	revascularized	with	autologous	ECs,	 it	provided	a	vascular	network	 for	
nutrient	 supply.	The	 vessels	 comprised	 a	diameter	 from	about	200	μm	until	 about	2–
20	μm	 in	 the	 capillary	 bed	 of	 the	 lumen.	 The	 cannulation	 before	 explantation	 and	
consecutive	 preservation	 of	 mesenteric	 arterial	 and	 venous	 vessels	 allowed	 the	
connection	of	the	vasculature	to	a	perfusion	bioreactor.	Thereby,	the	pedicles	served	as	a	
feeding	input	and	draining	outlet	for	perfusion	culture	and	mass	transfer	throughout	the	
scaffold111,112.	 The	 vascular	 structures	 were	 repopulated	 and	 matured	 ensuring	 a	
sufficient	nutrient	 supply	 for	 further	 implemented	 cells	 to	 establish	 tissue‐specific	 co‐
cultures	 on	 the	 luminal	 ECM	 ultimately	 generating	 vascularized	 tissue	 grafts	 (Fig.	 3).	
Cell	viability	and	functionality	of	 tissue‐specific	cells	was	proven	 in	vitro.	The	scaffolds	
intrinsic	properties	allowed	tissue	reconstruction	 in	vitro	proving	subsequent	vascular	
tightness	 upon	 in	 vivo	 anastomosis113.	 Furthermore,	 the	 preserved	mesenteric	 vessels	









Decellularized	 ECM	 scaffolds	 with	 preserved	 vascular	 structures	 derived	 from	 porcine	





Full	 tissue	 vascularization	 still	 depicts	 a	 major	 problem	 in	 TE	 for	 the	 generation	 of	
clinically	 relevant	 grafts.	 Pre‐vascularization	 of	 cell‐based	 scaffolds	 significantly	
improved	tissue	integration	upon	implantation.	However,	for	tissues	bigger	than	micro‐
scaled,	an	immediate	connection	to	the	host	circulation	is	required	for	sufficient	nutrient	
supply	 and	 graft	 vitality.	 The	 BioVaSc‐TERM®	 meets	 the	 mentioned	 requirements.	










cells	 necessary	 as	 well	 as	 implantation	 in	 small	 animal	models	 for	 preclinical	 animal	
studies.	Furthermore,	the	utilization	of	the	vessel	system	and	its	applicability	as	a	delivery	









To	demonstrate	 the	capacity	 to	maintain	co‐cultures,	various	 tissue‐specific	cells	were	
cultured	 in	 close	 proximity	 to	 the	 capillaries	 embedded	 inside	 the	 luminal	 ECM.	
Thereby,	the	 ex	 vivo	 generation	 of	 tissue‐like	 grafts	 was	 promoted.	 Demonstrating	
physiological	metabolic	functions	and	the	secretion	of	biologically	active	compounds	into	






















after	 approval	 from	 our	 institutional	 animal	 protection	 board,	 University	 Würzburg.	
Organ	explantation	was	performed	under	registration	reference	number	#	55.2	2532‐2‐
256	 and	 in	 vivo	 animal	 studies	were	 performed	 under	 registration	 reference	 number	
#2532‐2‐12.	Anesthesia	during	surgery	was	administered	by	Isoflurane	inhalation,	pain	
management	 was	 treated	 with	 Carprofen	 (dosage	 and	 application	 was	 5	 mg/kg	 s.c.)	
according	 to	 the	 recommendation	 of:	 'Pain	 therapy	 for	 laboratory	 animals	
GV‐SOLAS'‐guideline	 by	 the	 Committee	 for	 anesthesia	 and	 analgesia,	 in	
2015.	Upon	termination	of	the	experiments,	animals	were	sacrificed	in	accordance	with	

























Upcyte®	 hepatocytes,	 liver	 sinusoidal	 ECs	 and	 MSCs	 were	 stably	 transduced	 with	















































































































































































































































































































































































































































































































































































































































































































































psPAX2	 Packaging		 	 12260	 Addgene,	
Cambridge,	USA	



































Antigene		 Host		 Clone		 Concentra
tion		
Manufacturer		 Isotype		
aSMA	 mouse	 1A4	 1	µg/ml	 Abcam,	Cambridge,	UK	 IgG2a	
Caspase‐3,	
activated	
rabbit	 polyclonal	 2	µg/ml	 Abcam,	Cambridge,	UK	 Serum		











CK18	 mouse	 C‐04	 200	ng/ml	 Abcam,	Cambridge,	UK	 IgG1	






Ki67		 rabbit	 SP6	 1:100	 Abcam,	Cambridge,	UK	 IgG	
NG2		 mouse	 HMB45	 1:100	 Abcam,	Cambridge,	UK	 IgG1	
vWF	 mouse	 F8/86	 100	ng/ml	 DakoCytomation,	
Glostrup,	DK	
IgG1	




Antigene		 Dye		 Host		 Dilution		 Manufacturer		
Mouse		 Alexa	Fluor	488	 Donkey		 1:400	 ThermoFisher	Scientific	
GmbH,	DE	
Rabbit		 Alexa	Fluor	488	 Donkey	 1:400	 Invitrogen,	Darmstadt,	DE	
Guinea	Pig	 Alexa	Fluor	488	 Goat		 1:400	 Invitrogen,	Darmstadt,	DE	
Mouse		 Alexa	Fluor	555	 Donkey		 1:400	 Invitrogen,	Darmstadt,	DE	
Rabbit		 Alexa	Fluor	555	 Donkey	 1:400	 Invitrogen,	Darmstadt,	DE	
Mouse		 Alexa	Fluor	647	 Donkey		 1:400	 Invitrogen,	Darmstadt,	DE	




























The	 abdominal	 wall	 was	 disinfected	 and	 cut	 open	 by	 a	 median	 laparotomy	 (Fig.	 4).	
The	intestine	 was	 set	 aside	 at	 first	 to	 expose	 the	 mesenterica	 superior,	 the	 vessels	
supplying	 duodenum,	 jejunum,	 and	 ilium.	 Vessels	were	 uncovered	 carefully	 removing	
adjacent	lymph	nodes	and	possible	fat	and	connective	tissue	to	facilitate	cannulation	with	
a	24	gauge	catheter.	Arteria	mesenterica	superior	and	vena	mesenterica	superior	were	
individually	 cannulated	 and	 the	 cannulas	 fixed	 with	 a	 surgical	 thread	 to	 prevent	
dislocation.	Heparin	(100	IE/kg)	was	administrated	into	the	feeding	artery	via	the	placed	
cannula	and	flushed	through	the	intestinal	vascular	tree.	Flow	and	blood	clearance	was	
monitored	 visually.	 A	 flushed	 5	 to	 10	 cm	 long	 jejunal	 segment	 was	 chosen	 for	



































DIN	 EN	 ISO	 10993‐5	 for	 medicinal	 products.	 The	 acellular	 scaffold	 was	 incubated	 in	
1	ml	cell	culture	medium	per	3	cm2	for	72	h	at	37	°C	on	a	rocking	shaker.	Pure	cell	culture	
medium	incubated	alongside	served	as	control.	Meanwhile,	about	20,000	target	cells	were	
cultured	 for	24	h	 in	a	96	well	 format.	Culture	medium	was	discarded	on	 the	cells	and	







Up	 to	 25	mg	 tissue	was	 cut	 into	 pieces	 and	 combined	with	 180	 µl	 of	 ATL	 buffer	 and	
20	µl	proteinase	K	solution	in	a	microcentrifuge	tube.	Until	 thorough	lysis	the	mix	was	














Surgical	 implantations	of	 the	mBioVaSc‐TERM®	were	conducted	by	Dr.	 Johannes	Baur	










of	 the	 patency	 of	 the	 anastomosis	 and	 the	 pervading	 of	 the	 scaffold	 with	 blood	 the	
abdominal	cavity	was	closed	occluding	the	abdominal	musculature	and	closure	of	the	skin	




Animals	were	monitored	 on	 a	 daily	 basis	 upon	 indications	 of	 general	 condition,	 body	




































































































An	 aliquot	 of	 a	 cell	 suspension	 was	 mixed	 with	 trypan	 blue	 and	 about	 10	 µl	 of	 the	
suspension	 were	 transferred	 into	 a	 Neubauer	 chamber.	 Placed	 under	 a	 microscope,	
in	each	of	the	four	big	squares	white	appearing	living	cells	and	the	dead	cells	appearing	
blue	were	counted.	Determining	cell	number	per	ml,	 the	mean	of	all	 four	square	were	
calculated,	multiplied	by	 the	dilution	 factor	of	 the	original	cell	 suspension	with	 trypan	
blue,	as	well	as	multiplied	with	the	volume	of	the	chamber:	

















Cells	 were	 detached	 from	 adherent	 culture,	 counted,	 and	 cell	 suspension	 adjusted	 to	
about	1*106	cells/ml	of	fresh	cell	culture	medium	supplemented	with	10	to	20	%	FCS	and	





















on	Matrigel™‐coated	plates	until	 the	 formation	of	 liver	 organoids	by	 self‐organization.	
After	3	d	in	culture,	the	spheroidal	organoids	were	carefully	transferred	from	the	matrigel	





















of	 MTT	 to	 insoluble	 formazan	 and	 its	 intracellular	 deposition.	 The	 solution	was	 then	
discarded	and	200	µl	DMSO	with	25	µl	glycine	buffer	(0.1	M	glycine,	0.1	M	NaCl,	pH	10.5)	

















subsequently	100	µl	 fresh	 culture	medium	were	added	as	well	 as	100	µl	CellTiter	Glo	
reagent.	The	Tecan	luminescence	reader	allowed	for	shaking	the	culture	plate	for	2	min,	






venous	 cannulas	 into	 the	 vascular	 tree	 of	 the	 scaffold.	 Allowing	 cell	 adherence	 to	 the	
vascular	 walls,	 infusion	 was	 followed	 by	 a	 1	 h	 static	 incubation	 until	 a	 subsequent	
injection	into	both	vessels	and	another	1	h	static	incubation.	Dependent	on	scaffold	size,	
0.5	 to	 1	ml	 of	 a	 1x106	 cells/ml	 EC	 suspension	 was	 introduced	 per	 injection	 with	 an	
infusion	rate	of	4	ml/min.	To	allow	maturation	and	functional	 lining	of	 the	endothelial	
barrier	 on	 the	 vascular	 bed	 the	 scaffold	 was	 connected	 to	 a	 bioreactor	 in	 which	 the	
vascular	 system	 was	 perfused	 dynamically	 mimicking	 physiological	 blood	 pressure.	


















































































































































Haematoxylin	 stains	 the	 nuclei	 blue	 by	 binding	 of	 the	 dye‐metal	 complex	 to	





water.	 pH	 was	 adjusted	 to	 6.0	 with	 5	 M	 NaOH.	 Washing	 buffer	 was	 prepared	 with	































cells	 were	 additionally	 permeabilized	 with	 0.3	 %	 Triton‐X100	 in	 PBS	 for	 10	 min.	
Unspecific	binding	was	blocked	by	5	%	BSA	in	antibody	dilution	solution	during	at	least	
30	min.	 Primary	 antibody	was	 incubated	 o/n	 at	 4	 °C.	 Before	 and	 after	 1	 h	 secondary	




Whole	 mount	 sections	 were	 fixed	 and	 stained	 by	 immunofluorescence	 as	 described	
before.	 Optical	 clearing	 for	 light	 sheet	 microscopy	 was	 performed	 by	 a	 two‐step	




0.1	 M	 phosphate	 buffer	 was	 prepared	 using	 10.9	 g/l	 sodium	 phosphate	 dibasic,	
3.2	g/l	sodium	phosphate	monobasic,	and	pH	was	adjusted	to	7.3.	Cells	and	tissue	models	





4	%	PFA,	 and	 1	 %	 glutaraldehyde.	 Samples	 were	 washed	 afterwards	 three	 times	 in	




followed	 by	 10	min	 in	 100	 %	 ethanol,	 twice.	 Then	 samples	 were	 incubated	 in	
propylenoxide	for	10	min,	twice,	and	o/n	in	a	1:1	propylenoxide/epon	mixture.	The	next	











the	CO2	 incubator.	 200	µl	 of	 the	basolateral	 compartment	were	 transferred	 in	 a	 black	
96	well	 plate	 and	 analyzed	 upon	 fluorescent	 particles	 passing	 the	 barrier	 by	 a	





For	 barrier	 model	 maintenance	 it	 is	 crucial	 that	 the	 electrode	 was	 disinfected	 with	
70	%	ethanol	for	15	min	before	application.	For	reproducible	analysis	the	Millicell®	ERS‐
2	system	was	calibrated	before	each	usage,	the	electrode	was	equilibrated	in	fresh	cell‐






applied	 to	 the	 compartments	 separated	 from	 the	 cellular	 barrier	 and	 the	 electrical	
resistance	 determined.	 For	 each	 condition,	 the	 measurement	 was	 performed	 in	
triplicates.	 Cell	 free	 inserts	 served	 as	 negative	 control.	 Evaluation	of	 the	 actual	 TEER‐
value	from	the	determined	resistance	was	calculated	as:	
ܶܧܧܴ	ݒ݈ܽݑ݁	ሾΩ ∗ ܿ݉ଶሿ





To	 analyze	 vessel	 integrity	 and	 microvascular	 permeability	 real‐time	 fluorescence	
intravital	microscopy	was	 employed	 as	 described	 previously121.	 The	 graft	 was	 placed	
under	a	standard	inverted	microscope	and	perfused	with	carbogen‐gassed	PBS	solution	
at	 37	 °C.	 Intravital	 real‐time	 fluorescence	 was	 detected	 after	 infusion	 of	 either	 FITC‐
coupled	dextran	or	albumin	solution	in	PBS	or	blood	directly	into	the	vasculature	via	the	
arterial	 pedicle.	 For	 in	 vivo	 analysis	 the	 animal	 was	 kept	 under	 anesthesia	 while	 the	




Endothelial	 cells	 incorporate	 LDL	 through	 receptor‐mediated	 endocytosis.	
To	demonstrate	the	metabolic	function	the	ECs	inside	the	vessel	structures	the	graft	was	
exposed	to	10	µg/ml	AcLDL	for	4	h	at	37°	C	by	infusing	the	solution	through	the	arterial	





Segments	 of	 reendothelialized	 vessels	 were	 dissected	 and	 mounted	 on	 pins	 inside	 a	








a	 segment	 of	 about	 3	mm	was	mounted	 on	 the	 pins	 of	 each	 chamber.	 The	 pins	were	
tightened	and	the	vessel	segments	incubated	in	the	chambers.	After	1	h	of	equilibration,	







provided	 in	a	volumetric	 flask	placed	on	a	magnetic	stirrer.	pH	was	set	 to	7.5	and	 the	
volume	was	stocked	with	purified	water	to	a	final	volume	of	1	l.	The	generated	LB	medium	
was	split	into	two	500	ml	bottles,	to	each	3.25	g	agar‐agar	was	added,	and	brought	for	





















grow	 cultures	 of	 bacteria	 successfully	 transformed.	 The	 following	 day	 cultures	 were	




















blank,	 and	 samples	 were	 applied	 in	 duplicates	 into	 a	 black	 96	 well	 plate.	 To	 each,	
100	µl	pico	 green	 reagent	 was	 added	 and	 incubated	 together	 for	 2	 to	 5	 min	 while	
protected	 from	 light	 to	minimize	photobleaching.	Fluorescence	was	measured	with	an	

































with	 the	 appropriate	 restriction	 enzymes	 allowed	 DNA	 fragment	 generation	 for	








dependent	 temperature.	 Using	 fast	 digestion	 enzymes,	 a	 total	 volume	 of	 20	 µl	 was	
prepared	with	2µl	of	10x	fast	digest	buffer,	1	µg	DNA,	and	1µl	fast	digest	enzyme	incubated	
for	5	min	at	37	°C.	Vectors	were	digested	the	same	way	as	the	inserts.	To	prevent	self‐
ligation	 of	 vectors,	 dephosphorylation	 was	 performed	 using	 5	 units	 of	 Antarctic	
phosphatase	with	1	to	5	µg	of	digested	vector	DNA	in	2	µl	of	10x	buffer	in	a	total	volume	
of	20	µl	for	15	min	at	37	°C.	Reaction	was	heat	inactivated	for	5	min	at	70	°C.	Vector	and	








resulting	 in	 the	 expected	 fragment	 sizes	 were	 analyzed	 by	 gelelectrophoresis.	
Subsequently,	 HEK293T	 cells	 were	 transduced	 with	 the	 vector	 plasmid	 along	 with	













HEK	 cells	 and	 replaced	 with	 fresh	 culture	 medium	 supplemented	 with	 30	 %	 FCS	 to	



















medium	 exchange	 to	 allow	 for	 proliferation	 of	 the	 transduced	 cells.	 3	to	5	d	 after	
transduction	 cells	 were	 selected	 upon	 the	 implemented	 antibiotic	 in	 the	 beforehand	
determined	 concentration.	 If	 no	 antibiotic	 resistance	 was	 integrated	 but	 fluorescence	
was,	selection	could	be	conducted	via	FACS	sorting.		
Evidence	 of	 residual	 virus	 availability	 in	 the	 culture	medium	was	 investigated	 at	 the	
earliest	after	3	passages.	Therefore,	supernatant	of	the	transduced	cells	was	transferred	
onto	 HEK	 293T	 cells	 at	 about	 50	%	 confluency.	 Past	 72	 h	 of	 incubation,	 cells	 were	

























Coomassie	 stain	 solution	 was	 filtered	 after	 solving	 of	 250	 ml	 acetic	 acid,	
1,000	ml	methanol,	6.25	g	brilliant	blue	in	1,250	ml	purified	water.		
Destain	solution	consisted	of	10	%‐v/v	isopropanol	and	10	%‐v/v	acetic	acid.		
10	 ml	 10	 %	 resolving	 gel	 sufficient	 for	 two	 gels	 consisted	 of	 2.5	 ml	 lower	 tris,	





For	 each	 gel	 prepared,	 two	 glass	 slides	 were	 washed	 with	 purified	 water	 and	
70	%	ethanol.	 Spacers	were	 placed	 in	 between	 the	 glasses	 and	 placed	 as	 one	 into	 the	
clamping	system.	Resolving	gel	was	cast	up	to	two	thirds	in	between	the	glass	slides	and	
covered	with	purified	water	to	ensure	a	straight	horizontal	line	after	polymerization	for	
30	min.	Water	 was	 then	 removed	 and	 stacking	 gel	 was	 cast	 and	 sealed	 with	 a	 comb	
creating	the	pockets	after	polymerization	for	30	min.	Gels	in	glass	slides	were	clamped	in	










stain	 for	 at	 least	 1	 h	 incubation	 on	 a	 rocking	 shaker.	 To	 remove	 excessive	 Coomassie	













secondary	 antibody	 for	 1	 h	 at	RT.	Blots	were	 again	washed	 twice	 for	 5	min	 each	 and	
developed	immediately	after.	For	blot	development,	the	blot	was	covered	with	a	mixture	




For	 determination	 of	 α‐elastin	 content,	 tissue	 samples	 were	 incubated	 in	 750	 µl	 of	
0.25	M	oxalic	 acid	 at	 100	 °C	 for	 60	min.	 After	 cooling	 down	 to	 room	 temperature	 the	
samples	 were	 centrifuged	 for	 10	 min	 at	 10,000	 rpm	 to	 collect	 the	 supernatant.	
The	procedure	was	repeated	 for	two	more	times	until	 the	tissue	was	digested.	Of	each	
digest	duplicates	of	100	µl	were	mixed	with	100	µl	ice	cold	elastin	precipitation	reagent	






reagent.	Reaction	between	elastin	 and	dye	was	 allowed	while	90	min	 incubation	on	a	
rotational	 shaker.	 After	 centrifugation	 for	 10	 min	 at	 12,000	 rpm	 unbound	 dye	 was	
discarded.	 250	 µl	 dye	 dissociation	 reagent	 added,	 shortly	 vortexed,	 and	 incubated	 for	
10	min	to	disassociate	bound	dye	from	elastin.	200	µl	were	transferred	into	a	transparent	
96	well	plate	and	examined	at	513	nm.	Elastin	amount	directly	proportional	to	the	dye	is	















Insulin	 secretion	 of	 pancreatic	 islets	 was	 stimulated	 by	 glucose	 incubation	 after	
deprivation	with	KRB	buffer.	Therefore,	the	islets	were	pre‐incubated	in	3	mM	glucose	for	






























































All	 results	 are	 expressed	 as	 mean	 ±	 standard	 deviation	 (SD).	 Differences	 between	









The	 aim	 of	 this	 thesis	 was	 to	 generate	 a	 scaffold	 of	 rat	 intestine	 that	 resembles	 the	
structural	properties	of	 the	BioVaSc‐TERM®.	After	establishing	a	suitable	explantation	
strategy,	a	protocol	 for	detergent‐based	perfusion	decellularization	of	 the	scaffold	was	
developed.	The	miniaturized	version	of	 the	BioVaSc‐TERM®,	 that	 is	 referred	 to	as	 the	
mBioVaSc‐TERM®,	was	characterized	on	 its	 structure	and	composition	by	histological	
and	protein	biochemical	analyses.	Preservation	of	an	intact	vascular	system	was	analyzed	
by	 reendothelialization	 of	 the	 vessel	 structures,	 thereby	 demonstrating	 scaffold	
biocompatibility	 in	 vitro.	 Scaffold	 revascularization	 was	 utilized	 to	 maintain	 complex	
multicellular	co‐cultures	viable	to	perform	functional	metabolic	conversion	and	protein	
secretion	 analysis.	 Finally,	 implantation	 into	 rats	 demonstrated	 in	 vivo	 survival	 of	 the	





a	biological	 scaffold	 similar	 to	 the	 porcine	 BioVaSc‐TERM®.	 Focus	 was	 on	 an	 easy	





rat	 jejunal	 segments.	 The	 explantation	 is	 depicted	 in	 figure	 4,	 indicating	 the	 incisions	
made	 for	 a	 laparotomy	 (Fig.	 4A)	 to	 gain	 access	 into	 the	 abdominal	 cavity	 and	 the	
subsequent	 preparation	 of	 the	 cannulation	 and	 dissection	 of	 the	 intestinal	 segment.	
The	mesenteric	vessels	(Fig.	4B;	highlighted	by	arrowheads),	which	branch	off	from	the	
abdominal	 aorta	 and	 leading	 into	 the	 hepatic	 portal	 vein,	 were	 dissected	 from	
surrounding	 connective	 tissue	and	 fat.	The	 superior	mesenteric	artery	and	antidromic	







PBS	perfusion	 indicated	 an	 intact,	 perfusable	 arteriovenous	 loop.	 A	 jejunal	 segment	
cleared	from	blood	was	ligated	(Fig.	4E)	to	prevent	leakage	and	to	enable	maintenance	of	
an	intact	arteriovenous	circulation	after	extraction.		






was	 opened	with	 a	median	 laparotomy	 and	 vertical	 relief	 cuts	 (represented	 by	 dotted	 lines).	
(B)	The	superior	mesenteric	artery	(indicated	by	‘A’)	and	the	superior	mesenteric	vein	(indicated	













Based	 upon	 a	 literature	 survey	 referring	 to	 decellularization	 methods	 of	 intestinal	
structures,	relevant	protocols116,117,	mainly	using	sodium	deoxycholate	(SDC)	and	DNase	
for	 perfusion	 decellularization,	were	 initially	 reproduced	 and	 subsequently	 optimized	
upon	the	devices	in‐house	as	well	as	the	structural	ECM	preservation	and	cell	removal.		
Thereby,	a	detergent‐based	protocol	for	perfusion	decellularization	of	both,	the	vascular	















and	 D’)	 qualitatively	 proved	 DNA	 clearance.	 Fluorometric	 and	 spectral	 photometric	
quantification	confirmed	that	more	than	80	%	of	the	DNA	was	removed	to	a	content	of	
25	ng	DNA	/mg	dry	weight	of	the	tissue	(Fig.	5H).	To	determine	whether	the	remaining	
DNA	 was	 of	 high	 or	 low	 molecular	 weight,	 the	 fragment	 length	 was	 analyzed	 by	
gelelectrophoresis.	 Low	 molecular	 weight	 DNA	 might	 not	 be	 detrimental	 but	 could	
potentially	implicate	immunoproliferative	effects	on	host	lymphocytes124,	whereas	high	





The	gelelectrophoretical	 analysis	 of	 the	 residual	 DNA	 proved	 the	 absence	 of	 high	







Despite	 an	 expected	 loss	 of	 overall	 matrix	 mass	 during	 decellularization,	
Masson’s	trichrome	staining	(Fig.	5E	and	E’)	confirmed	the	conservation	of	the	major	ECM	
components	 such	 as	 collagen	 as	 well	 as	 the	 removal	 of	 cell	 cytoplasm.	 Besides	 the	
structural	 components	providing	a	 framework	 for	 cells,	 functionality	 of	 the	 scaffold	 is	
determined	by	elastic	fibers	(Fig.	5F	and	F’).	In	addition	to	the	histological	evaluation	of	
the	 scaffold,	 quantitative	 determination	 by	 protein	 biochemical	 analysis	 revealed	 the	
extent	of	matrix	protein	preservation.	 In	contrast	 to	DNA	removal,	 the	majority	of	 the	
analyzed	ECM	proteins	were	 retained.	About	70	%	of	 total	 collagen	 (Fig.	5I),	 the	most	
abundant	structural	protein	constituting	the	scaffolds	connective	tissue127,	was	confirmed	
to	be	preserved	after	decellularization.	Again,	considering	a	loss	of	matrix,	about	60	%	of	
the	 elastic	 fibers	was	 preserved	 compared	 to	 the	 native	 tissue	 (Fig.	 5J).	 Furthermore,	
electron	 microscopic	 analysis	 (Fig.	 5L‐N)	 revealed	 the	 preservation	 of	 intact	 ECM	
structures,	such	as	the	basement	membrane.		

















of	 the	 decellularization	 protocol.	 (B+B‘)	 Representative	 macroscopic	 pictures	 of	 the	 scaffold.	
In	contrast	 to	 (B)	 the	 native	 jejunal	 segment,	 (B’)	 the	 decellularized	 scaffold	 appeared	
transparent.	(C‐F‘)	Histological	analysis	of	(C‐F)	the	native	rat	jejunal	segment	in	comparison	to	
(C‘‐F‘)	 the	 decellularized	 mBioVaSc‐TERM®:	 (C+C‘)	 Representative	 pictures	 of	 H&E	 staining.	
(D+D‘)	Feulgen‐stained	 samples	 depict	 DNA	 residues.	 (E+E‘)	 Masson‘s	 Trichrome	 staining	
representing	 residual	 collagen	 (turquois),	 muscle	 fibers	 (dark	 red),	 as	 well	 as	 cell	 cytoplasm	
(pink)	between	the	scaffold	and	native	tissue.	(F+F‘)	Elastica	vanGieson	reaction	eliciting	elastic	
fibers	 within	 the	 matrix.	 (G)	 DNA	 fragment	 length	 separation	 via	 gelectrophoretic	 analysis.	
(H)	Quantitative	 determination	 of	 the	 DNA	 amount	 in	 the	 native	 and	 decellularized	 tissue.	
(I+J)	Quantification	of	the	major	ECM	components:	(I)	Collagen	and	(J)	Elastin	before	and	after	















To	 investigate	 the	 preservation	 of	 the	 decellularized	 vessel	 system	 in	 the	 mBioVaSc‐
TERM®,	 the	 acellular	 vascular	 network	 was	 repopulated	 with	 human	 dermal	
microvascular	endothelial	cells	(hdmEC).		
Endothelial	cells	were	isolated	from	human	foreskin,	separated	from	other	cell	types,	and	
expanded	 according	 to	 an	 in‐house	 established	 protocol.	 Furthermore,	 the	 isolated	
hdmECs	 were	 lentivirally	 transduced	 either	 with	 a	 green	 fluorescent	 protein	 (GFP)	
containing	expression	vector	or	with	the	DNA	sequence	for	GFP	clonally	replaced	for	red	
fluorescent	 protein	 (RFP),	 to	 express	 either	 GFP	 or	 RFP,	 respectively.	 Thereby,	 non‐
invasive	live	imaging	of	the	reendothelialized	vascular	structures	was	feasible.	To	ensure	
the	 endothelial	 character	 after	 genetic	 modification,	 the	 cells	 were	 subsequently	
characterized	 upon	 their	 growth	 kinetics,	 protein	 expression	 profile,	 and	 barrier	
formation	capacity	to	assure	vessel	formation	capability	and	functionality.		




the	 cells	 analyzed,	 expressed	 the	 membrane	 glycoprotein	 CD105.	 The	 angiopoietin	
receptor	 TIE2	 was	 detected	 on	 67.8	%	 of	 the	 cells.	 CD34,	 characteristic	 for	 capillary	
endothelial	cells,	was	verified	on	95.1	%	of	the	hdmECs.	VE	cadherin	was	proven	to	be	
expressed	on	98.7	%.	CD146,	the	melanoma	cell	adhesion	molecule	(MCAM),	was	verified	
on	 94.7	%	of	 the	 hdmECs.	 Only	 vascular	 endothelial	 growth	 factor	 (VEGF)‐receptor	 2	
could	not	be	identified	by	FACS.		
Besides	 the	 presence	 of	 functional	 EC	 surface	 proteins,	 the	 ability	 of	 the	 genetically	













Furthermore,	 fluorescein	 isothiocyanate	 (FITC)‐coupled	 dextran	 was	 applied	 apically	
onto	the	cell	 layer	to	evaluate	endothelial	permeability.	Fluorospectrometrical	analysis	
quantified	that	after	 two	weeks	of	culture	only	about	1	%	of	 the	FITC‐coupled	dextran	
passed	 the	 established	 endothelial	 barrier	 (Fig.	6D).	 Thereafter,	 the	 barrier	 integrity	
remained	 stable	 throughout	 the	 culture	 period	 of	 35	 d	 preventing	 most	 of	 the	 low	
molecular	weight	compound	to	pass	the	endothelial	barrier.	
Characterizing	 the	 genetically	 modified	 GFP‐/RFP‐tagged	 hdmECs,	 the	 cells	 exhibited	
endothelial	 markers	 specific	 for	 cell‐cell	 junctions,	 cell‐ECM	 adherence,	 blood	 vessel	











Primary	 human	 dermal	microvascular	 and	 GFP/RFP‐tagged	 hdmECs	were	 analyzed	 upon	 cell	
type‐specific	properties.	(A)	FACS	analysis	revealed	EC‐characteristic	markers	for	angiogenesis	
(CD31	and	CD105),	blood	vessel	formation	(TIE2),	and	cell	adhesion	(VE‐Cad,	CD34,	and	CD146).	
(B)	CellTiter	 Glo	 analysis	 indicated	 the	 proliferative	 potential	 of	 the	 employed	 ECs.	 Proving	
endothelial	 barrier	 properties	 of	 a	 confluent	 EC	 layer,	 (C)	 TEER	measurement	 demonstrated	












incubation	 to	 enable	 attachment	 to	 the	 basement	 membrane,	 the	 reendothelialized	





pump	 installed	 inside	 an	 incubator	was	 adapted	 for	 the	 use	 of	 the	mBioVaSc‐TERM®	
(Fig.	7D).	To	maintain	a	physiological	pressure	profile	at	all	times	throughout	the	culture	
period,	 the	applied	pressure	was	sensor‐controlled	and	automatically	regulated	by	the	
implementation	 of	 an	 automated	 computer‐aided	 feedback	mechanism	 regulating	 the	
pumping	device.	Both,	arterial	and	venous	pressure	profiles	were	individually	monitored	
representing	their	physiological	conditions	(Fig.	7D).		
For	 the	 evaluation	 of	 vascular	 leakage,	 the	 hdmEC‐endothelialized	mBioVaSc‐TERM®	
was	perfused	with	phenol	red	in	PBS	and	with	blood.	Infusion	of	phenol	red	through	the	
arterial	pedicle	resulted	in	unobstructed	leakage	of	the	fluid	through	the	vascular	barrier	







were	 repopulated	with	 either	 GFP‐	 or	 RFP‐expressing	 hdmECs,	 respectively	 (Fig.	 7G).	
By	means	of	fluorescently	tagged	cells,	it	was	feasible	to	monitor	the	repopulation	of	the	
vascular	system	by	live	imaging	techniques	to	discriminate	the	arterial	and	venous	vessels	





















Continuous	 monitoring	 of	 physiological	 parameters,	 such	 as	 simulated	 blood	 pressure,	
temperature,	and	oxygenation	enabled	constant	computer‐aided	regulation	of	culture	conditions	










Cytocompatibility	 of	 the	 scaffold	 was	 assessed	 by	 repopulation	 with	 hdmECs.	




Examining	 whether	 the	 cultured	 hdmECs	 retained	 their	 endothelial	 character	 in	 a	
3D	vessel	 environment,	 the	 presence	 of	 functional	 endothelial	 markers	 was	 verified.	
The	hdmECs	 inside	 the	 vascular	 structures	 were	 shown	 to	 be	 positive	 for	 CD31	
(Fig.	8B	and	E)	and	vWF	(Fig.	8C	and	F)	by	immunohistological	stainings.	However,	based	
on	 the	 analysis	 of	 the	whole	mount	 stainings	 (Fig.	8E	and	F),	 highlighting	 the	 hdmECs	






Characterization	 of	 hdmECs	 populating	 the	 vascular	 system	 of	 the	 mBioVaSc‐TERM®	 after	
maturation	 in	 a	 perfusion	 bioreactor	 system.	 (A)	Metabolic	 activity	 of	 the	 ECs	 populating	 the	
branching	 capillary	 network	 of	 the	 mBioVaSc‐TERM®	 by	 a	 colorimetric	 MTT	 assay.	
Immunohistological	 detection	 of	 the	 endothelial	 marker	 (B)	 CD31	 and	 (C)	 vWF	 in	 capillary	
structures	 in	 cross	 sections	 of	 the	 luminal	 part	 of	 the	 revascularized	 mBioVaSc‐TERM®	
(highlighted	 by	 arrowheads).	 (D)	 Life‐dead	 staining	 differentiating	 viable	 (FDA)	 and	
apoptotic/necrotic	(PI)	ECs.	Top	view	on	a	whole	mount	immunofluorescence	(IF)	staining	of	the	







In	 summary,	 hdmECs	 used	 for	 repopulation	 of	 the	 whole	 vascular	 network	 of	 the	
mBioVaSc‐TERM®	were	demonstrated	to	be	viable	and	vital,	and	to	display	EC‐specific	
characteristics	 after	 infusion	 and	 culture	within	 the	 scaffold	during	 long‐term	 culture.	
Furthermore,	 the	 originally	 arterial	 and	 venous	 vascular	 structures	 could	 be	
discriminated	 within	 the	 scaffold	 by	 infusion	 of	 genetically	 modified	 GFP‐	 or	 RFP‐
expressing	 hdmECs	 through	 the	 respective	 cannulas.	 The	 integrity	 of	 the	 vascular	
network	forming	a	tight	barrier	in	the	afferent	feeding	and	efferent	draining	vessels	and	
its	 arteriovenous	 loop	 was	 demonstrated	 by	 the	 return	 of	 blood	 through	 the	 venous	
pedicle	of	the	scaffold	after	arterial	infusion.	Macroscopically,	the	blood	was	clearly	visible	





EC	 barrier	 that	 is	 completely	 removed	 in	 decellularized	 tissues	 and	 usually	 hardly	
accomplished	to	be	reestablished	thoroughly.	Therefore,	the	volume	returned	from	the	




















mBioVaSc	+	ECs	‐	PBS).	 Perfusing	 the	 reendothelialized	mBioVaSc‐TERM®	with	 blood,	
the	 venous	 return	 was	 restored	 to	 30	 %	 of	 the	 native	 in	 vivo	 situation	 (Fig.	 9;	
mBioVaSc	+	ECs	‐	blood).		
However,	 during	 in	 vitro	 culture,	 the	 perfusion	 with	 standard	 culture	 media	 hardly	
reestablished	venous	return	due	to	lacking	extracellular	tissue	pressure	and	no	colloid	





Figure	 9.	 Venous	 return	 profile	 at	 different	 stages	 of	 mBioVaSc‐TERM®	
establishment	
The	volume	returned	 through	 the	venous	outlet	upon	arterial	 infusion	 through	 the	mBioVaSc‐







Beyond	 the	 examination	 of	 the	 endothelial	 character,	 cellular	 metabolic	 activity	 and	
vitality,	as	well	as	the	capacity	to	form	an	intact	barrier	within	the	vessel	structures	of	the	






hdmECs.	 Thereby,	 hdmEC	 functionality	 was	 demonstrated	 for	 cells	 populating	 the	
vascular	network	of	the	mBioVaSc‐TERM®	(Fig.	10A).		
After	 verification	 of	 the	 reproducibility	 of	 the	 revascularization,	 the	 end‐point	
examinations	were	replaced	by	non‐destructive	live	imaging	of	the	vascular	structure.		
Investigating	 the	 EC	 barrier	 integrity	 of	 the	 reendothelialized	 mBioVaSc‐TERM®,	 the	
vascular	network	was	perfused	with	fluorescently	coupled	dextran	and	albumin,	solved	





sign	 of	 major	 leakage	 out	 of	 the	 vascular	 bed	 demonstrating	 vascular	 tightness	 and	
integrity.	 Remarkably,	 while	 perfusion	 with	 blood,	 the	 fluorescent	 particles	 could	 be	
individually	 detected	 (Fig.	10D).	 Thereby,	 the	 particles	 could	 be	 tracked	 following	 the	
arterial	 influx	and	a	delayed	efflux	 in	 the	adjacent	venous	vessel.	The	perfusion	of	 the	


















solved	 in	 blood	 perfusion.	 The	 perfusion	 of	 the	 fluorescent	 particles	 through	 the	 capillaries	






of	 the	 revascularized	 mBioVaSc‐TERM®.	 Vessel	 integrity	 and	 vascular	 tightness	 was	












4.2.4	 Analysis	 of	 the	 differentiation	 capacity	 of	 hPSC‐derived	 mesothelial	 cells	
towards	ECs,	pericytes,	and	aSMA+	cells	within	the	mBioVaSc‐TERM®	
In	parallel	to	the	generation	of	the	mBioVaSc‐TERM®,	a	cooperation	partner	developed	a	
protocol	 to	 generate	 human	 pluripotent	 stem	 cell	 (hPSC)‐derived	mesothelial	 cells134:	
multipotent	vascular	progenitors	 that	can	be	 further	differentiated	 into	ECs,	pericytes,	
and	smooth	muscle	cells.	They	were	described	to	self‐assemble	to	vessel‐like	structures	
and	support	vascularization135	and	tissue	repair136	in	vivo.		
Here,	 hPSCs	 differentiated	 towards	 the	 mesothelium	 lineage	 by	 Thomas	 Colunga	
(Dalton	Lab,	PI:	 Prof.	Dr.	 Stephen	Dalton,	 Center	 for	Molecular	Medicine,	University	 of	
Georgia,	 Georgia,	 USA),	 were	 infused	 into	 the	 mBioVaSc‐TERM®	 connected	 to	 the	
perfusion	bioreactor.	Within	the	3D	scaffold,	the	cells	were	further	differentiated	based	
on	the	protocol	established	by	T.	Colunga.		
Whole	mount	analysis	 (Fig.	11A	and	B)	of	 the	vessels	revealed	vascular	 lining	with	all	
three	 differentiated	 cells	 types.	 Cross	 sections	 of	 different	 vessels	 with	 distinctive	
diameters	demonstrated	the	cellular	composition	(Fig.	11C‐D’’).	CD31‐positive	ECs	were	
lining	the	inner	vascular	barrier	of	all	vessels	with	neural/glial	antigen	(NG)	2‐positive	
pericytes137	 in	 close	proximity.	 In	 contrast	 to	 the	ECs,	pericytes	were	distributed	only	
sparsely.	Besides	ECs	and	pericytes,	capillaries	were	not	enclosed	by	smooth	muscle	cells	
(SMCs).	 Larger	 vessels,	 however,	 were	 surrounded	 by	 thick	 layers	 of	 alpha‐smooth	
muscle	actin	(aSMA)‐positive	cells.		
Displaying	the	presence	of	all	three	vascular	cell	types	differentiated	from	one	progenitor,	
demonstrated	 the	 capacity	 of	 the	 hPSC‐derived	 mesothelial	 cells	 and	 the	 established	
differentiation	protocol	to	differentiate	the	cells	from	one	progenitor	lineage	into	three	
distinct	 lineages	 within	 a	 3D	 ex	 vivo	 model.	 The	mBioVaSc‐TERM®	with	 its	 inherent	
vascular	network	enables	the	further	examination	of	cellular	differentiation	in	an	in	vivo‐
like	 3D	 environment	 resembling	 the	 native	 extracellular	 vascular	 architecture.	
Furthermore,	 with	 the	 mBioVaSc‐TERM®	 connected	 to	 the	 bioreactor	 setup,	 further	
stimulation,	such	as	shear	stress	by	pulsatile	perfusion	mimicking	a	physiological	in	vivo‐
















conjunctions	 remained	 to	 be	 improved,	 primarily	 by	 enhancing	 seeding	 and	 culture	
conditions.	Nevertheless,	mesothelial	cells	appeared	to	represent	a	viable	alternative	cell	
source	accounting	for	their	potential	to	differentiate	into	ECs,	pericytes	and	SMA+	cells	in	











Mesothelial	 cells	 were	 infused	 in	 the	 vascular	 structures	 of	 the	 mBioVaSc‐TERM®	 and	
differentiated	 towards	 ECs,	 pericytes,	 and	 SMCs.	 The	 cellular	 character	 was	 determined	 by	
immunohistological	 staining	against	CD31,	NG2,	and	aSMA,	 respectively.	Vascular	composition	
and	 cellular	 distribution	 was	 examined	 immunohistologically	 on	 (A,	 B)	 whole	 mounts	 of	 the	











After	 revascularization	 of	 the	 mBioVaSc‐TERM®	 vessel	 system,	 co‐cultures	 were	
established	 within	 the	 luminal	 compartment	 of	 the	 scaffold	 to	 further	 demonstrate	






Establishing	 consecutively	 a	 co‐culture	 system	 of	 two	 or	 more	 different	 cell	 types	 to	
generate	 a	 functional	 tissue	 graft	 requests	 great	 demands	 on	 media	 composition	
providing	critical	cues	for	all	employed	cells.		
At	first,	the,	viability,	vitality,	and	metabolic	activity	of	cells	co‐cultured	in	the	lumen	of	
the	 scaffold	 was	 analyzed	 to	 be	 maintained	 throughout	 long‐term	 culture,	 indicating	
biocompatibility	of	the	mBioVaSc‐TERM®.	This	was	verified	for	each	cell	line	used	for	co‐





important	 role	 for	 ECM	 turnover138.	 Therefore,	 these	 cells	 were	 used	 initially	 to	
demonstrate	 the	 combinability	 of	 different	 cell	 types	 with	 distinct	 media	 and	
supplementations	for	cell	viability	when	co‐cultured	within	the	mBioVaSc‐TERM®.		
In	 a	 first	 step,	 the	 suitability	 of	 the	mBioVaSc‐TERM®	 for	 co‐culture	 of	 hdmECs	with	
Human	dermal	fibroblasts	was	analyzed.	The	fibroblasts	were	adapted	to	be	cultured	in	
EC	 culture	 medium	 simplifying	 the	 media	 composition	 applied	 to	 the	 co‐culture.	
The	fibroblasts	were	cultured	either	directly	on	the	ECM	of	the	inner	luminal	wall	in	close	
proximity	 to	 the	embedded	capillaries	 (Fig.	12A)	or	 the	 fibroblasts	were	enclosed	 in	a	
collagen	gel	cast	inside	the	lumen	(Fig.	12B).	For	both	luminal	culture	methods,	the	cells	
were	 analyzed	 by	 MTT	 and	 FDA/PI	 demonstrating	 cellular	 vitality	 and	 viability	










Schematic	 representation	 of	 cells	 cultured	 inside	 the	 lumen	 of	 the	 mBioVaSc‐TERM®	 either	
(A)	directly	on	the	luminal	ECM	adjacent	to	the	capillaries	or	(B)	embedded	in	a	collagen	hydrogel	









aim	 was	 to	 establish	 the	 mBioVaSc‐TERM®	 as	 a	 platform	 technology	 for	 complex	
multicellular	 tissue	 or	 organ	 culture.	 Therefore,	 the	 demand	 for	 optimized	 media	
supplementation	 and	 sustained	 nutrient	 supply	 was	 increased	 by	 incorporating	
metabolic	highly	demanding	liver‐like	organoids	inside	the	scaffold	lumen,	as	the	liver	is	
a	densely	vascularized	organ	highly	active	in	enzymatic	conversion139.		
Spheroidal	 liver‐like	 organoids	 were	 generated	 (Fig.	 13A	 and	 B)	 as	 described118	 and	
transferred	 into	 the	 lumen	 of	 the	 revascularized	 mBioVaSc‐TERM®,	 placed	 in	 close	
proximity	 to	 the	 capillaries	 embedded	 in	 the	 luminal	 wall	 (Fig.	 13C).	 Similar	 to	




was	 demonstrated	 by	MTT	 analysis.	 Immunohistochemical	 analysis	was	 performed	 to	





Hepatocyte	 functionality	 was	 examined	 by	 enzymatic	 conversion	 of	 acetaminophen,	
dextrorphan,	 6ß‐OH‐testosteron,	 and	 4‐OH‐diclofenac	 by	 the	 cytochromes	 CYP1A2,	
CYP2D6,	 CYP3A4,	 and	 CYP2C9,	 respectively.	 For	 enzymatic	 conversion	 analysis,	 the	
organoids	were	explanted	from	the	scaffold	and	exposed	to	the	respective	compound	to	
determine	the	cytochrome	conversion	rates	by	high	performance	liquid	chromatography	











































even	 with	 complex	 and	 demanding	 multicellular	 organoids	 maintained	 viable	 and	
functional.	 Beyond	 nutrient	 delivery	 to	 sustain	 vitality,	 the	 vasculature	 could	 also	 be	
utilized	to	distribute	drugs	secreted	by	cells	cultured	in	the	lumen	of	the	scaffold.		
In	a	pilot	experiment,	 the	capacity	of	 the	mBioVaSc‐TERM®	as	a	scaffold	 for	cells	 that	
secrete	 signaling	 molecules,	 such	 as	 hormones,	 cytokines,	 and	 growth	 factors,	 was	
investigated.	
To	achieve	this,	cells	secreting	Activin	A	and	Myostatin	were	generated.	Both,	Activin	A	















proliferation	 inhibitory	 effect	 in	 a	 dilution	 series	 in	 a	 bioassay	 for	 each	 protein:	with	











from	 supernatant	 from	 standard	 2D	 cell	 culture	 flask	 as	well	 as	 from	 the	 bioreactor	 and	 the	
vascular	compartment	by	ELISA	quantification.	(B)	The	secreted	proteins	were	applied	in	a	dose‐





from	 constitutively	 secreting	 cells	 as	 well	 as	 protein	 distribution	 throughout	 the	
bioreactor	system,	indicated	the	applicability	of	the	mBioVaSc‐TERM®	as	a	drug	delivery	
system.	However,	to	also	demonstrate	the	capacity	of	the	scaffold	to	maintain	complex	
native	 cell	 cluster	 naturally	 secreting	 proteins	 upon	 a	 highly	 regulated	 feedback	
mechanism	viable	and	functional,	pancreatic	 islets	were	co‐cultured	inside	the	 luminal	
compartment	of	the	revascularized	mBioVaSc‐TERM®.		
Neonatal	 pig	 islet‐like	 cell	 clusters	 (NICC)	 represent	 a	 cluster	 of	 different	 cell	 types	
composing	a	pancreatic	islet	isolated	that	can	be	utilized	for	cell	therapy	in	type	1	diabetes	
patients141	due	to	their	endocrine	insulin	secretory	activity	when	matured.		
NICCs	 were	 isolated	 by	 Dr.	 Elisabeth	 Kemter	 (Molecular	 Animal	 Breeding	 and	
Biotechnology,	PI:	Prof.	Dr.	Eckhard	Wolf,	LMU	München,	Munich,	DE),	co‐cultured	in	the	
lumen	 of	 the	 revascularized	 mBioVaSc‐TERM®	 (Fig.	 15A),	 and	 investigated	 for	 their	
viability	and	functionality	when	cultured	in	vitro.		
At	 first,	 the	 amount	 of	 NICCs	 to	 be	 cultured	 per	 area	 on	 the	 ECM	 and	 media	








the	 endothelialized	 mBioVaSc‐TERM®	 accordingly.	 The	 metabolic	 activity	 of	 the	 cell	
clusters	was	analyzed	by	MTT	for	up	to	20	days	in	culture	(Fig.	15B).	Noticeable	thereby,	
the	islets	tended	to	cluster	around	the	vascular	structures.	H&E	staining	on	cross	sections	
of	 the	 cultured	 organoids	 within	 the	 scaffold	 demonstrated	 that	 the	 cells	 lost	 their	




To	 determine	 endocrine	 functionality	 of	 the	 cells,	 insulin	 secretion	was	measured	 by	
ELISA	 analysis	 of	 the	 supernatant.	 Therefore,	 the	 cells	 were	 pre‐incubated	 in	
3	mM	glucose	for	30	min	before	glucose	stimulated	insulin	secretion	incubating	the	islet	
containing	scaffolds	with	3,	5,	and	10	mM	glucose.	Comparing	the	insulin	release,	there	




Furthermore,	 the	 influence	 of	 additional	 co‐cultures	 on	 NICC	 viability	 and	 insulin	
secretion	was	investigated	infusing	the	NICCs	along	with	ECs	and	mesenchymal	stem	cells	
(MSC)	 inside	 the	 luminal	 part	 of	 the	mBioVaSc‐TERM®	 cultured	with	 10	mM	 glucose	
supplementation.	Performing	an	 insulin	ELISA	with	 the	 respective	supernatants,	 there	
was	 a	 slight	 yet	 insignificant	 increase	 in	 insulin	 release	 detected	 over	 time	 (Fig.	15F).	
This	trend	was	demonstrated	to	be	similar	for	all	co‐culture	conditions.	However,	when	
NICCS	 were	 co‐cultured	 with	 hdmECs	 or	 with	 MSCs	 and	 hdmECs,	 the	 overall	 insulin	




In	 summary,	 even	 though	 the	 spheroidal	 shape	 was	 lost,	 the	 long‐term	 viability	 and	
vitality	of	NICCs	within	the	mBioVaSc‐TERM®	was	demonstrated.	In	consideration	of	the	
immature	 character	 of	 the	 neonatal	 isolated	 islet‐like	 cell	 clusters,	 a	 sustained	 basal	









Figure	 15.	 Vascularized	 endocrine	 pancreatic	 tissue	 generation	with	 functional	
insulin	secretion.		
NICCs	 cultured	 in	 the	 reendothelialized	 mBioVaSc‐TERM®	 to	 develop	 an	 endocrine	 tissue.	
(A)	NICCs	 were	 cultured	 inside	 the	 luminal	 compartment	 in	 close	 proximity	 to	 the	 perfused	
endothelialized	 capillary	 network.	 (B)	 Colorimetric	MTT	 assay	 determining	metabolic	 activity	
revealed	 a	 distinct	 staining	 of	 the	 ECs	 inside	 the	 vascular	 structures	 and	 the	 islets	 clustering	
around	vessels.	(C)	H&E	overview	stain	on	cross	sections	showed	a	cell	monolayer	residing	on	the	









sustain	 functional	 enzymatic	 conversion	 as	 well	 as	 secretion	 of	 bioactive	 signaling	











to	 be	 maintained	 viable	 as	 well	 as	 to	 support	 sustained	 biologically	 active	 protein	
















well	 as	 the	 caudal	 vena	 cava	proved	 to	 be	 appropriate	 for	 the	 anastomosis	with	 little	
vascular	offset	and	a	high	blood	flow.	Furthermore,	the	abdominal	area	provided	enough	




aorta	as	well	as	 the	caudal	vena	cava	(Fig.	16B)	were	prepared	 for	anastomosis	of	 the	
preserved	mesenteric	arterial	and	venous	vessels	of	the	mBioVaSc‐TERM®,	respectively,	
by	 clearing	 and	 freeing	 them	 from	 connective	 tissue	 attached	 to	 the	 vasculature.	








where	 it	 spread	out	 into	 the	 vast	branching	 capillaries	 (Fig.	 16D).	The	 constant	blood	
perfusion	through	the	whole	vascularization	of	the	scaffold	as	well	as	the	venous	return	
were	proven	by	manual	drainage	of	the	vessels.	For	this,	the	blood	perfused	vessels	of	the	







connected	 to	 the	 animal’s	 circulation	 was	 investigated	 in	 terms	 of	 vascular	 stability,	
perfusion,	 and	 leakage	 over	 a	 course	 of	 30	minutes	 (n	 =	 4).	 In	 all	 animals,	 no	 visible	
leakage	was	detected	at	any	time	point	nor	position,	confirming	the	in	vitro	results	when	
perfusing	the	scaffold	with	blood.	Additionally	performed	manual	drainages	at	different	
positions	 of	 the	 scaffold	 proved	 the	 continuous	 unidirectional	 blood	 flow	 in	 feeding	
arterial	 and	 draining	 venous	 vessels	 as	 well	 as	 in	 the	 luminal	 capillaries	 (Fig.	 16D).	
Representative,	in	two	of	the	animals,	the	vascular	tightness	of	the	mBioVaSc‐TERM®	and	
its	perfusion	connected	 to	 the	animal’s	 circulation	was	 further	confirmed	by	real‐time	
intravascular	 fluorescence	 microscopy.	 For	 this,	 fluorescently	 labeled	 albumin	 was	
injected	into	the	jugular	vein	of	the	anesthetized	animal	with	the	abdomen	opened	and	
the	 mBioVaSc‐TERM®	 anastomosed	 to	 the	 animal’s	 circulation	 as	 mentioned	 before.	
Thus,	 the	 injected	 tracer	 was	 distributed	 systemically	 throughout	 the	 animal’s	 blood	
system	 and	 was	 also	 detected	 within	 the	 vasculature	 of	 the	 anastomosed	 mBioVaSc‐
TERM®	within	less	than	1	minute	and	was	distinctly	visible	thereafter.	After	cutting	off	
the	 anastomosis	 to	 explant	 the	 scaffold	 (Fig.	 16E),	 immunohistochemical	 analysis	
confirmed	the	presence	of	CD31‐positive	cells	in	all	examined	vascular	compartments	of	
the	scaffolds,	i.e.	in	the	larger	vessel	in	close	proximity	to	the	anastomosis	(Fig.	16F),	in	the	










(A)	 The	 abdominal	 wall	 of	 the	 recipient	 rat	 was	 opened	 by	 a	 median	 laparotomy.	 (B)	 The	
infrarenal	 part	 of	 the	 aorta	 abdominalis	 and	 the	 caudal	 part	 of	 the	 vena	 cava	 (indicated	 by	
arrowheads)	were	dissected	from	surrounding	connective	tissue.	(C)	Side‐to‐end	anastomosis	of	
arterial	 and	 venous	 vessels	 of	 the	 mBioVaSc‐TERM®	 with	 the	 abdominal	 vasculature	 of	 the	
animal	(highlighted	by	arrowhead).	(D)	Blood	inflow	into	the	vascular	system	of	the	mBioVaSc‐








After	 the	 intraoperative	confirmation	of	 the	 feasibility	and	tightness	of	 the	established	
anastomosis	 and	 the	 reendothelialized	 mBioVaSc‐TERM®	 vessels,	 the	 scaffold	 was	
analyzed	upon	its	vascular	integrity	and	biocompatibility	in	successive	studies	for	up	to	
120	days.		





signs	 of	 pain	 nor	 of	 altered	 behavior	 aside	 from	 early	 evident	 dizziness	 due	 to	 the	













behavior	 was	 observed	 as	 compared	 to	 control	 animals	 during	 the	 whole	 study.	
The	mBioVaSc‐TERM®	 was	 tolerated	 by	 the	 rats	 without	 any	 notable	 complications,	
incompatibility	 or	 rejection	 except	 for	 one	 animal.	 The	 weight	 gain	 of	 this	 one	 rat	
stagnated	and	exhibited	signs	of	acute	abdominal	pain	after	seven	days	postoperatively	

















due	 to	 indications	 of	 altered	 or	 abnormal	 behavior;	 2	 –	 termination	 in	 case	 of	 persisting	 or	









easily	 identified	 being	 embedded	 in	 between	 the	 rat’s	 intestine.	 At	 first	 glance,	 the	
macroscopic	 morphology	 of	 the	 mBioVaSc‐TERM®	 (Fig.	18A)	 and	 its	 anastomosis	
(Fig.	18A;	 inlet)	was	widely	unchanged	 to	 its	 original	 appearance	before	 implantation.	








































tissue	 in	 vivo.	 To	 proof	 that	 the	 mBioVaSc‐TERM®	was	 capable	 of	 being	 utilized	 for	
maintaining	tissue	culture	in	vivo,	the	vasculature	was	lined	with	hdmECs	and	spheroidal	
liver	 organoids	 were	 generated	 and	 implemented	 into	 the	 lumen	 of	 the	 vascularized	
scaffold.		






(Fig.	19B’’)	 to	 the	 anastomosis,	 CD31+	 ECs	were	 displayed	 to	 tightly	 line	 the	 vascular	
structures	of	different	diameter.	Additionally,	integrated	liver‐like	organoids	in	the	in	vivo	
study,	were	examined	immunohistochemically	for	the	cell	characteristic	markers	of	the	
three	 implemented	organoid	 cell	 types.	Hepatocytes	were	 verified	by	CK18	 (Fig.	19C),	





depicted	 CD31‐positive	 cells	 in	 all	 observed	 vessels.	 The	 CD31+	 ECs	 lining	 capillaries	
















(Fig.	 19P’)	 vessels	 and	 only	 a	 scattered	 CD31+	 EC	 detection	 in	 the	 luminal	 capillaries	
(Fig.	19P’’).	The	fate	of	the	implemented	liver	organoids	matched	the	EC‐examination	of	












Characterization	 of	 the	mBioVaSc‐TERM®	upon	 (A,	H,	O)	macroscopic	 appearance	 and	 (B’‐U)	
immunohistochemical	 analysis	 after	 implantation	 for	 (A‐G)	 3,	 (H‐N)	 7,	 and	 (O‐U)	 30	 days.	
The	inlets	show	a	magnification	of	the	blood‐perfused	vascular	tree.	The	dashed	lines	indicate	the	
cross	sections	for	staining	against	CD31:	(B,	I,	P)	proximal	to	the	anastomosis,	(B’,	I’,	P’)	on	distal	
parts	 of	 the	 vasculature,	 and	 (B’’,	 I’’,	 P’’)	 through	 the	 lumen.	 Liver‐like	 organoids	 were	
implemented	 in	 the	 luminal	 compartment,	 confirmed	 by	 staining	 against:	 (C,	 J,	 Q)	 CK18,	
(D,	K,	R)	CD31,	and	(E,	L,	S)	CD90	for	hepatocytes,	endothelial	cells,	and	mesenchymal	stem	cells,	



























can	 be	 pharmaceutically	 compensated	 but	 the	 only	 definitive	 treatment	 is	 organ	
transplantation.	 Nevertheless,	 the	 availability	 of	 donor	 organs	 is	 limited144.	 Hence,	
there	is	an	increasing	demand	for	improved	tissue	regeneration	or	bio‐engineered	tissue	
substitutes	 with	 clinical	 relevance	 being	 biocompatible,	 non‐	 immunogenic,	 non‐
thrombogenic,	but	biologically	functional.	While	recent	advances	in	TE	succeeded	in	the	
generation	 of	 flat	 2D	 or	 hollow	 tissues145,146,	 even	 towards	 clinical	 application76,147,	
functional	 tissue	 engineering	 of	 complex	 solid	 organs	 is	 still	 unmet	 due	 to	 the	 lack	 of	
whole	 tissue	 nutrition.	 Nevertheless,	 progression	 towards	 whole	 organ	 generation	 is	
being	made	in	small	animal	models	by	whole	organ	decellularization	and	recellularization	





consequential,	 generating	 a	 vascularized	 matrix	 as	 framework	 for	 subsequent	 tissue	
establishment	and	maturation.		
Resulting	thereof,	aim	of	this	thesis	was	to	purge	a	rat	intestinal	segment	from	host	cells	






With	 the	 BioVASc‐TERM®,	 Prof.	 Heike	 Walles	 already	 established	 of	 a	 vascularized	





research	 into	 clinical	 application113.	 Ongoing	 research	 continuously	 extends	 the	
applicability	 of	 the	BioVaSc‐TERM®	and	 its	 related	 SIS	 onto	 the	 generation	of	 further	
tissues	and	disease	models	such	as	skin150,	meniscus151,	intestinal152,	and	various	tumor	
models153‐155.	 However,	 although	 the	 size	 of	 the	 porcine‐derived	 scaffold	 enables	 the	











of	 tissues	 on	 a	 collagenous	 scaffold	 embedding	 a	 vascular	 network.	 After	 in	 vitro	
maturation	 in	 a	 perfusion	 bioreactor	 system	 applying	 tissue‐specific	 stimulation,	
the	established	 graft	 could	 then	 immediately	 be	 anastomosed	 to	 a	 patient’s	 blood	
circulation	 to	mediate	 sustained	 in	 vivo	 survivability.	 The	 underlying	 reason	 allowing	
immediate	anastomosis	and	vascular	blood	supply	was	the	preservation	and	utilization	
of	 the	 innate	 vascularization	 of	 the	 scaffold’s	 3D	 ECM	 structure.	 For	 miniaturization	
purpose,	those	properties	had	to	be	necessarily	reflected.		
Regarding	 scaffold	 size,	 the	 dimensions	 were	 considered	 to	 be	 as	 small	 as	 possible	
requiring	only	a	minimum	amount	of	 cells	 for	 repopulation,	enabling	proof	of	 concept	
studies	 in	 small	 animal	 models,	 and	 minimal	 invasive	 implantations	 in	 patients.	
Nevertheless,	a	sufficient	amount	of	functional	cells	had	to	be	implemented	to	assure	a	
functional	physiologic	therapeutic	effect.	Furthermore,	a	vascular	in‐	and	outlet	had	to	be	
feasible	 to	 be	 anastomosed	 without	 vascular	 offset	 to	 enable	 perfusion	 and	 prevent	
leakage	or	rupture.		
A	 lot	of	synthetic	scaffolds	are	biocompatible,	highly	reproducible	in	their	preparation,	





technically	 not	 yet	 feasible	 to	 suffice	 the	 requirements	 mimicking	 a	 natural	
vascularization	including	one	afferent	and	one	efferent	vessel	interconnected	by	a	dense	
capillary	bed	embedded	in	a	3D	ECM	meshwork.		
Therefore,	 the	 natural	 jejunal	 segment	 indicated	 ideal	 properties	 as	 a	 biologically	
vascularized	scaffold	establishing	a	platform	technology	comprising	a	tubular	collagen‐
based	ECM	with	an	embedded	vascular	network.	Hence,	for	down	scaling	of	the	porcine‐
derived	 BioVaSc‐TERM®,	 a	 naturally	 occurring	 ECM	 homologue	 from	 a	 small	 animal	
model	 had	 to	 be	 identified	 facilitating	 scaffold	 explantation,	 decellularization,	 and	
subsequent	 tissue	 graft	 reconstruction.	 The	 most	 important	 part	 thereby	 was	 the	
feasibility	 of	 the	 explantation	 while	 preserving	 the	 vascular	 structures	 for	 further	
processing.		
The	most	prevalent	small	animal	models	employed	 for	research,	being	mouse	and	rat,	
were	 considered	 first	 for	 evaluation	 of	 the	 feasibility	 of	 vascular	 cannulation	 and	
retention.		
At	first	consideration,	the	mouse	model	was	empirically	assessed	for	miniaturization	of	a	
biologically	 vascularized	 scaffold	 due	 to	 its	 small	 size,	 prevalent	 usage,	 and	 low	 cost.	
Mouse	whole	 organ	 decellularization	 via	 cannulation	 and	partial	 recellularization	was	
shown	 previously	 for	 heart158	 and	 lung159,160.	 However,	 in	 the	 described	 studies,	 the	
cannulation	was	achieved	via	the	heart.	The	vessels	directly	supplying	the	intestine	were	
too	 thin	 and	 their	 diameter	 too	 narrow	 to	 introduce	 an	 indwelling	 cannula.	 As	 the	
vasculature	cannot	efficiently	be	utilized	without	cannulation,	the	initial	selection	of	the	
mouse	model	as	donor	for	scaffold	miniaturization	was	dismissed	due	to	the	vasculature	
being	 inapplicable	 for	 stable	 permanent	 cannulation	 and	 thereby	 for	 perfusion	
decellularization	and	reestablishment	of	the	vascular	system.		
The	 preservation	 of	 the	 vascular	 tree	 was	 the	 major	 requirement	 for	 the	 scaffold.	
Taxonomically,	 the	 next	 bigger	 prevalent	 small	 animal	 model	 of	 the	 murine	 family	



























For	 further	 processing,	 a	 well‐balanced	 decellularization	 protocol	 was	 critical	 for	
effectively	 removing	 cellular	 materials	 provoking	 an	 adverse	 inflammatory	 response	
upon	 implantation123	 while	 maintaining	 native	 ECM	 structure	 facilitating	
recellularization162,163.		
In	TE,	a	multitude	of	various	methods	have	been	established	for	the	decellularization	of	
different	 tissues	 and	 organs164	 based	 on	 chemical,	 enzymatic,	 and	 mechanical	
procedures126	 targeting	 different	 components.	 Despite	 an	 extensive	 experience	 with	
decellularization	 of	 porcine	 jejunal	 segments113,	 the	 miniaturization	 was	 not	








At	 the	 same	 time,	 Totonelli	 et	 al.	 published	 a	 protocol	 describing	 a	 rat	 intestinal	
decellularization	 method116.	 Consequently,	 the	 protocol	 described	 was	 reproduced,	
adopted	 on	 the	 in‐house	 available	 laboratory	 equipment,	 and	 optimized	 upon	 cell,	
especially	 DNA	 removal	 as	well	 as	 ECM	preservation.	 The	 overall	matrix	 composition	
appeared	already	well	preserved	and	the	original	host	DNA	was	removed	to	a	great	extent.	
The	detergent	concentrations	and	incubation	times	were	only	customized	upon	the	in‐
house	 operational	 procedures	 but	 were	 kept	 to	 the	 described	 suggestion	 as	 close	 as	
feasible.	With	the	DNase	incubation	adjustment	to	be	performed	at	37	°C	instead	of	room	
temperature	 the	 enzymatic	 DNA	 cleavage	 activity	 was	 increased.	 However,	
with	biocompatibility	 assays	 indicating	 poor	 cell	 survival	 of	 freshly	 seeded	 cells	 after	




Initially,	 to	minimize	 the	 incubation	 time	with	more	 detrimental	 chemicals,	 ultrapure	













such	 as	 SDC,	 sodium	 dodecyl	 sulfate,	 or	 Triton	X‐200,	 are	 commonly	 used	 for	
decellularization	 as	 they	 can	 thoroughly	 solubilize	 cell	 and	 nuclear	 membranes	 and	
completely	 denature	 proteins,	 these	 properties	 also	 account	 for	 damaging	 ECM	
proteins165.	 SDC	 appeared	 to	 be	 the	 least	 detrimental	 of	 the	 ionic	 detergents	 but	





components.	 Alkaline	 solutions	 are	 rather	 suitable	 for	 the	 decellularization	 of	 dense	
structures	as	they	harshly	degrade	structural	matrix	components.	Non‐ionic	detergents,	
proteases,	 and	 chelators,	 however,	 are	 in	 general	 very	mild	 and	 thereby	 ineffective	 in	
complete	cellular	remnant	removal.	To	reduce	the	amount	and	exposure	time	of	chemical	
agents,	 cellular	disruption	can	be	achieved	beforehand	by	repeated	 freeze‐thaw	cycles	
instead	 of	 osmotic	 cell	 lysis.	 However,	 even	 though	 it	 does	 not	 significantly	 impair	






















ultrastructural	 analysis	 (Fig.	5L‐N)	as	 critical	 structural	ECM	proteins	 could	mostly	be	














high	 molecular	 weight	 chromosomal	 DNA	 by	 electrophoretic	 analysis	(Fig.	5G).	
Official	benchmarks	for	effectively	decellularized	tissues	for	implantation	are	only	hardly	
available.	 Besides	 guidelines	 on	 sterility168	 and	 endotoxin	 amount176,	 recommended	
criteria	are	the	lack	of	nuclei,	and	residual	dsDNA	below	50	ng	per	mg	dry	weight	and	
200	base	pairs	in	length126	to	avoid	host	immune	responses177.		
Besides	 host	 cellular	 DNA178,	 also	 bacteria	 are	 capable	 of	 evoking	 immunogenic	 graft	
rejection	 or	 residual	 decellularization	 solutions	 might	 elicit	 local	 inflammation	 or	




process,	 residual	 LPS	 can	 elicit	 proinflammatory	 responses	 leading	 to	 systemic	
inflammation,	with	subsequently	increased	microvascular	permeability	and	consecutive	





recellularization.	 To	 indicate	 the	 capability	 of	 the	 mBioVaSc‐TERM®	 to	 establish	 a	
platform	technology	for	functional	graft	generation,	the	preserved	basement	membrane	
of	 the	 vascular	 tree	 was	 revascularized.	 Metabolic	 activity	 and	 cell	 viability	 were	









on	 xenogenic	 cells184,185	 most	 conveniently	 assayed	 quantitatively	 by	 ELISA186.	
However,	alpha‐Gal	 analysis	was	 not	 considered	 due	 to	 the	manifold	 results	 attesting	
biocompatibility	 together	with	 the	similar	positive	experience	made	with	 the	BioVaSc‐







based	 on	 a	 previously	 published	 method116,117.	 Effectively	 preserving	 the	 original	
intestinal	 architecture	 while	 efficiently	 removing	 host	 cells	 resulted	 in	 an	 acellular	
scaffold	 of	 plain	 ECM	meeting	 the	 demands	 and	 benchmarks	 for	 clinical	 applicability.	









between	 the	 intra‐	 and	 extravascular	 space.	 Beyond,	 haemocompatibility	 of	 a	 scaffold	









disrupted	 due	 to	 the	 decellularization	 process	 uncovering	 the	 underlying	 collagen	
network	 directly	 exposing	 a	 highly	 abundant	 matrix	 component	 with	 prothrombotic	
properties193,194.	Coagulation	is	part	of	the	humoral	defense	specifically	activated	when	
blood	 interacts	 with	 subendothelial	 layered	 collagens	 and	 vWF195	 to	 stop	 blood	 loss.	
However,	facing	an	implanted	scaffold	with	vascular	structures	dominated	by	collagen	the	
subsequent	 coagulation	 will	 result	 in	 thrombosis	 ultimately	 completely	 blocking	 the	
vascular	 access	 to	 the	 scaffold.	 Successively,	 the	 established	 tissue	 will	 become	
undernourished	and	finally	apoptotic	causing	more	harm	to	the	patient.		
Therefore,	the	vessel	system	of	the	scaffold	was	successfully	recellularized	with	human	




Before	 vascular	 recellularization	 of	 the	 scaffold,	 primary	 isolated	 hdmECs	 were	
lentivirally	 transduced	 for	 either	 GFP	 or	 RFP	 expression	 to	 enable	 live	 imaging.	
Thereafter,	 they	 were	 characterized	 upon	 their	 cellular	 markers196	 relevant	 for	
vasculogenesis,	 angiogenesis,	 mitogenesis,	 migration,	 permeability,	 cell‐cell	 contact,	
blood	vessel	formation,	as	well	as	their	ability	to	form	functional	barriers129	(Fig.	6).	
CD31	is	a	cell	surface	marker	on	endothelial	cells	for	intercellular	junctions,	critical	for	
angiogenesis,	 and	 a	 prevalently	 applied	 marker	 for	 EC	 identification.	 CD34	 is	 mostly	
present	 on	 hematopoietic	 stem	 cells	 and	 capillary	 endothelial	 cells.	 CD31	 and	 CD34,	
in	combination,	 characterize	 vascular	 endothelial	 cells	 with	 high	 specificity.	 CD105,	
also	known	as	Endoglin	(ENG),	is	a	membrane	glycoprotein	and	auxiliary	receptor	for	the	
TGF‐beta	 receptor	 complex	 with	 a	 crucial	 role	 in	 angiogenic	 endothelial	 cells	 due	 to	
affecting	cytoskeletal	organization	and	migration	during	vascular	remodeling.	TIE2	is	an	
angiopoietin	 receptor	 on	 the	 cell	 surface,	 crucial	 for	 blood	 vessel	 formation.	
The	determined	VE	cadherin	is	crucial	in	vascular	endothelial	cell‐cell	adhesion	and	major	
determinant	 of	 endothelial	 permeability.	 CD146,	 the	 melanoma	 cell	 adhesion	
molecule	(MCAM),	is	highly	expressed	in	cells	of	the	blood	vessel	wall,	 linking	the	cells	







VEGF,	 thereby	 highly	 important	 for	 vasculogenesis	 and	 angiogenesis,	 as	 well	 as	
mitogenesis	and	migration.	However,	upon	cell	confluency	VEGFR‐2	gets	internalized	by	
contact	inhibition197	potentially	explaining	the	lack	of	positive	detection	by	FACS	analysis.		
In	 total,	 the	 isolated	 cells	 were	 homogeneously	 positive	 for	 endothelial	 marker	 and	
especially	functional	markers	such	as	cell‐cell	and	cell‐ECM	adhesion,	as	well	as	important	
marker	 for	 angiogenesis	 and	 blood	 vessel	 formation.	 Furthermore,	 the	 capability	 to	
proliferate	and	to	form	a	tight	barrier	was	demonstrated	by	TEER	and	FITC	permeability	





endothelial	 lining	 facilitates	 hemocompatibility	 of	 a	 collagenous	 scaffold,	 avoiding	
coagulation	when	in	contact	with	blood192.	Revascularization	was	already	demonstrated	
for	the	BioVaSc‐TERM®	in	vitro111	as	well	as	when	anastomosed	to	the	brachial	vascular	
bundle	 of	 a	 human	 arm113.	 Furthermore,	 vascular	 structures	 of	 a	 rat‐derived	
decellularized	intestinal	segment	were	already	used	to	determine	the	angiogenic	capacity	
in	vitro198.	The	rat‐derived	segment	was	to	date	only	demonstrated	to	facilitate	 in	vitro	
reendothelialization	 of	 individual	 vascular	 channel	 segments	 by	 demonstrating	 vessel	
formation,	 a	 competence	 for	 neovascularization198	 and	 to	 exhibit	 pro‐angiogenic	
properties	 facilitating	 vessel	 ingrowth	 indicated	 by	 an	 in	 vivo	 chicken	 chorioallantoic	
membrane	(CAM)	assay116.		
Pursuing	 full	 graft	 vascularization	 to	 generate	 fully	 vascularized	 tissues,	 thorough	






basement	membrane	 the	 cells	were	 able	 to	migrate	 and	 proliferate	 in	 the	 preformed	






interconnection	 of	 both	 in	 the	 capillary	 bed,	 demonstrating	 a	 circulatory	
network	(Fig.	7G).		
In	 summary,	 scaffold	 revascularization	 was	 established,	 demonstrating	 typical	
endothelial	markers	(Fig.	8B,	C,	E,	and	F),	functionality	(Fig.	9	and	10A),	viability	(Fig.	8A),	
vitality	(Fig.	8D),	and	barrier	 integrity	 (Fig.	10B‐D)	of	 the	ECs	 lining	 the	arteriovenous	









Examining	 revascularization,	 the	 ECs	 were	 lining	 the	 arteriovenous	 tubular	 vascular	
network	demonstrating	typical	endothelial	markers,	functionality,	vitality,	and	viability	
while	embedded	in	a	3D	environment.		
Supporting	 maturation	 of	 the	 vascular	 endothelial	 barrier,	 physiological	 in	 vivo‐like	
conditions	 were	 mimicked	 using	 computer	 aided	 incubator	 and	 bioreactor	
systems	(Fig.	7C	and	D).	Temperature	and	gas	were	controlled	as	well	as	physiological	
pressure	 onto	 the	 vessels	 system	 was	 applied	 by	 pulsatile	 perfusion.	 The	 thereby	
occurring	 shear	 stress	 in	 the	 vasculature	 simulates	 the	 hemodynamic	 forces	 onto	 the	
endothelial	 cells	 stimulating	 maintenance	 of	 vascular	 homeostasis203,204,	
vascular	conductivity205,	vascular	barrier	 integrity78,	maintenance	of	vessel	branches85,	
as	well	as	arteriogenesis206.		
Vascular	 flow,	 arterial	 and	 venous	 circulation,	 and	 endothelial	 barrier	 integrity	 was	
demonstrated	by	 intra	vital	 fluorescence	microscopy	perfusing	with	PBS	 (Fig.	7E)	and	
blood	(Fig.	7F)	as	well	as	by	determination	of	the	venous	return	(Fig.	9).	The	perfusion	
through	 the	 whole	 scaffold,	 especially	 through	 the	 established	 arteriovenous	 loop,	












in	 the	 mBioVaSc‐TERM®	 after	 perfusion	 culture	 showing	 flow	 and	 culture	 media	
transport	 through	 the	mesenteric	vessels	but	 leakage	of	 fluid,	 indicated	by	phenol	 red	
leakage	(Fig.	7E),	through	the	capillary	bed	in	the	former	gut	lumen.		
In	native	vasculature	most	of	the	leaked	fluid	is	reabsorbed	into	the	lymphatic	system,	
which	was	not	 realizable	 for	 the	mBioVaSc‐TERM®	cultured	 in	vitro	 in	 the	bioreactor	
setup.	The	amount	of	 fluid	reabsorbed	 into	 the	venous	capillaries	 is	dependent	on	 the	
colloid	osmotic	pressure	gradient	between	intra‐	and	extravascular	space	and	hydrostatic	
pressure.	At	the	arterial	end	of	the	capillaries,	hydrostatic	pressure	prevails	forcing	fluid	
out	 of	 the	 vasculature.	 With	 fluid	 extrusion,	 hydrostatic	 pressure	 reduces	 within	 the	
capillary	until	colloid	osmotic	pressure	overbalances	hydrostatic	pressure	at	the	venous	
end	leading	to	reabsorption	of	the	fluid.	However,	since	the	arterial	hydrostatic	pressure	







thereby,	 not	 establishing	 a	 gradient.	 This	 might	 explain	 the	 low	 venous	 return	 when	
perfusing	with	both,	PBS	and	culture	medium,	as	when	perfusing	with	blood,	the	venous	









organism,	 this	 issue	 is	 overcome	 by	 pumping	 the	 blood	 towards	 the	 heart	 by	
vasoconstriction	 of	 the	 vessels	 themselves	 or	 by	 squeezing	 local	 veins	 during	 skeletal	
muscle	 contractions	 or	 breathing66.	 In	 case	 of	 the	 mBioVaSc‐TERM®	 cultured	 in	 the	
bioreactor	 system,	 smooth	muscle	 cells	were	 lacking	as	well	 as	 a	 “muscular	pump”	or	
“respiratory	pump”.	Nevertheless,	while	perfusing	the	arterial	pedicle	the	perfusion	pump	
of	the	bioreactor	system	created	a	negative	pressure	at	the	venous	pedicle	aiding	venous	
pressure	 and	 venous	 return.	 To	 increase	 the	 venous	 return	 within	 the	 bioreactor	
improving	vascular	maturation,	the	intravascular	hydrostatic	also	the	necessary	colloid	
osmotic	pressure	have	to	be	established	and	maintained202.	This	might	be	mitigated	by	
using	different	media	 for	 vascular	perfusion	 and	 for	 graft	 culture.	Therefore,	 the	 total	
serum	 protein	 concentration	 inside	 the	 vessel	 has	 to	 be	 higher	 than	 extravascular	 to	
ensure	 osmotic	 fluid	 inflow	 after	 capillary	 filtration208.	 Similar	 effects	 were	 indicated	
perfusing	the	mBioVaSc‐TERM®	 in	vitro	with	whole	blood:	unobstructed	flow	through	
the	 vasculature,	 retention	 of	 proteins	 solved	 in	 blood,	 and	 venous	 return	 could	 be	




Heparinized	 whole‐blood	 perfusion	 through	 the	 revascularized	 mBioVaSc‐
TERM®	(Fig.	7F,	 9,	 and	 10D)	 revealed	 no	 thrombosis	 in	 the	 scaffold.	 Interestingly,	
perfusion	of	blood‐isolated	platelets	also	revealed	no	adhesion	to	the	vessel	when	lined	
with	 ECs	 in	 contrast	 to	 EC‐free	 scffolds,	 which	 is	 essential	 for	 blood	 coagulation	 and	
assessable	in	vitro210,211.	Obviously,	the	used	endothelial	cells	formed	tight	barriers	and	
with	endothelial	 lining	of	a	 scaffold	platelet	adhesion	was	diminished	 facing	perfusion	
with	whole‐blood	isolated	platelets.		
In	summary,	considering	that	the	mBioVaSc‐TERM®	was	cultured	in	a	bioreactor	system	
with	culture	media	 it	was	obvious	 to	not	be	able	 to	 fully	 reestablish	 the	native	 in	vivo	
circulation	 and	 venous	 return:	 the	 oncotic	 pressure	 was	 similar	 intra‐	 as	 well	 as	
extravascular	due	to	ubiquitously	available	medium	and	vasoconstriction	was	not	feasible	
due	 to	 missing	 smooth	 muscle	 cell	 layers.	 Nevertheless,	 mimicking	 native	 conditions	
perfusing	with	blood	enabled	a	restoration	of	 the	venous	return	of	40	%	compared	 to	











In	 this	 thesis,	 hPSCs	 that	 were	 differentiated	 into	 the	 mesothelium	 lineage	 were	
demonstrated	 to	 be	 differentiated	 into	ECs,	 pericytes	 and	 SMCs	within	 the	mBioVaSc‐
TERM®	 providing	 3D	 vessel	 structures.	 This	 fortified	 the	 established	 differentiation	
protocol	 by	 Thomas	 Colunga	 (Dalton	Lab,	 PI:	 Prof.	 Dr.	 Stephen	 Dalton,	 Center	 for	
Molecular	Medicine,	University	of	Georgia,	Georgia,	USA)	as	well	as	 the	capacity	of	 the	
mBioVaSc‐TERM®	as	platform	for	vascular	TE.		
The	 visceral	 mesothelium	 is	 a	 thin	 epithelial	 layer	 surrounding	 internal	 organs212.	
During	development,	 a	 fraction	 of	 those	 cells	 undergoes	 epithelial	 to	 mesenchymal	
transition	invading	the	underlying	tissue	and	contributes	to	the	vascular	system213,214.		
Cultured	and	differentiated	in	the	vascular	system	of	the	mBioVaSc‐TERM®,	the	spatial	
distribution	 of	 the	 cells	 resembled	 the	 native	 vessel	 composition	 (Fig.	11).	 However,	
the	vessels	were	only	sparsely	populated	and	functionality	of	the	muscular	layer	as	e.g.	by	




Moreover,	 hPSCs	 differentiated	 into	 the	 mesothelium	 lineage	 might	 be	 utilized	 to	
reestablish	the	visceral	mesothelial	layer	‐	typically	present	on	internal	organs	‐	around	
the	mBioVaSc‐TERM®.	Enveloping	 the	 scaffold	with	 a	 layer	 of	mesothelial	 cells	might	
reduce	the	incidence	of	peritoneal	adhesions.		
In	 summary,	 hPSC	 technology215	 was	 employed	 to	 differentiate	 cells	 towards	 ECs,	
pericytes,	and	SMCs	from	one	common	progenitor,	 lining	 the	vessels	of	 the	mBioVaSc‐
TERM®.	 Implementation	 of	 those	 three	 different	 cell	 types	 potentially	 enables	 the	
generation	 of	 a	 diversified	 vascular	 network	 superior	 to	 EC	 only	 in	 terms	 of	 vascular	












Despite	 the	whole	vascular	 tree	of	 the	mBioVaSc‐TERM®	seemed	 to	be	 recellularized,	
not	all	 capillary	 branches	 were	 observed	 to	 be	 perfused	 during	 intra	 vital	







mass	 EC	 infusion	 might	 be	 avoided	 by	 modifying	 the	 recellularization	 method	 by	
resuspending	 the	 ECs	 in	 higher	 volumes	 and	 slower	 successive	 infusion.	




Furthermore,	 pursuing	 complete	 endothelialization,	 vascular	 progenitor	 cells	 were	
proven	to	be	promising	cell	sources	for	in	vitro	vascularization	in	TE44,102	as	they	are	even	
capable	 of	 restoring	 functional	 vascular	 endothelium217	 and	 enhancing	
neovascularization	in	an	ischemic	environment	in	vivo218.	The	crucial	influence	of	these	
progenitors	in	vascular	repair	and	regeneration219	could	be	exploited	to	close	eventual	
gaps	 in	 the	 endothelial	 lining	 of	 the	 vascular	 branches	 by	 perfusion	 of	 vascular	 or	
endothelial	progenitors	after	initial	recellularization.		
In	addition,	oxygenation	of	culture	media220	might	result	 in	 improved	quality	of	grafts	
generated.	 With	 oxygen	 saturation	 being	 overall	 one	 of	 the	 most	 vital	 criteria,	








with	 only	 gaseous	 oxygen	 provided	 in	 the	 atmosphere	 of	 the	 incubator.	 Furthermore,	
avoiding	 the	 risk	 of	 hypoxic	 conditions	 might	 improve	 cell	 growth,	 differentiation,	
maintenance,	and	subsequently	experimental	validity.		
Nevertheless,	 these	 results	 reflected	 the	difficulty	of	 the	 full	 restoration	of	 the	natural	
capillary	network	due	to	its	complexity.	However,	the	in	vitro	generation	of	vessels	with	





reendothelialized	 with	 hdmECs,	 bearing	 perfusable	 and	 discriminable	 arteriovenous	
transitions	in	the	capillary	bed.	A	venous	return	was	established	utilizing	colloid	osmotic	
pressure	perfusing	with	whole	blood	excluding	undefined	leakage	besides	the	interstitial	
fluid	 homeostasis	 through	 the	 capillary	 diffusion.	 Thrombosis	was	 not	 observed	 even	
with	 whole	 blood	 perfusion	 leading	 to	 the	 assumption	 that	 a	 tight	 haemocompatible	
vascular	 endothelial	 barrier	 was	 established,	 though	 hard	 to	 consistently	 prove	
considering	 the	 vast	 branched	 vessel	 network.	 The	 functional	 arteriovenous	 vascular	
reconstruction	 depicted	 by	 sophisticated	 techniques	 e.g.	 3D	 light	 sheet	 and	
intravital	microscopy	 impressively	 demonstrated	 a	 hallmark	 in	 vascular	 tissue	
engineering.		
However,	 pursuing	 full	 graft	 vascularization,	 only	 an	 endothelialization	was	 achieved.	
The	additional	 implementation	 of	 pericytes	 and	 smooth	muscle	 actin‐positive	 cells	 as	
indicated	by	mesothelial	cell	differentiation	(Fig.	10)	might	enable	the	generation	of	fully	
functional	 vessels	 and	 would	 depict	 a	 milestone	 in	 vascular	 tissue	 engineering.	










Considering	 the	 varying	 compositions	 of	 artery,	 arterioles,	 capillaries,	 venules,	 and	
veins222	 to	 be	 implemented	 into	 the	 complex	 branching	 vascular	 network	 of	 the	
mBioVaSc‐TERM®	the	cellular	composition	might	be	more	efficiently	studied	in	simpler	
set‐ups	such	as	vessels	with	only	one	defined	vascular	structure.	With	the	gained	insight	
into	 vessel	 dissection,	 de‐	 and	 recellularization	 a	 follow‐up	 study	 focusing	 on	 single	
straight	 vessels	 might	 further	 promote	 vascular	 TE	 and	 advance	 its	 translation	 into	




With	 revascularization	of	 the	mBioVaSc‐TERM®,	 the	 scaffold	was	demonstrated	 to	be	
suitable	for	cell	culture	and	nutrient	and	gas	supply	was	established	to	feed	cells	for	tissue	
graft	 development	 on	 the	 ECM	 of	 the	 former	 gut	 lumen	 (Fig.	 12).	 Expanding	 the	
applicability	of	the	mBioVaSc‐TERM®,	after	seeding	ECs	in	the	vessel	structures	various	
other	 cell	 types	 –	 including	multicellular	 organoids	 –	were	 co‐cultured	 in	 the	 luminal	
compartment.		
Therefore,	culture	conditions	were	individually	adapted	to	the	need	of	the	implemented	
cell	 types,	 subsequently	 demonstrating	 maintained	 cell	 viability	 and	 function.	
Media	composition	was	not	trivial	to	compose	as	different	cells	with	distinct	demands	for	
growth	factors,	cytokines,	and	hormones	were	cultured	together.		
Furthermore,	 the	 endothelial	 structures	 provided	 a	 distribution	 system	 to	 feed	 co‐
cultured	cells	but	also	to	function	as	distribution	system	to	deliver	compounds	to	the	cells	





also	 be	 feasible	 for	 secreted	 proteins	 to	 enter	 the	 vascular	 system	 via	 the	
capillary	network	 enabling	 drug	 secreting	 cells	 to	 release	 compounds	 into	 the	










tissue	 viable	 and	 functional,	 liver‐like	 organoids118	 were	 integrated	 in	 the	 luminal	
scaffold	(Fig.	 13C)	 as	 tissue	 model	 that	 might	 serve	 for	 prospective	 toxicology	 and	
metabolism	studies115.	
In	 a	 preliminary	 work118	 liver‐like	 organoids	 were	 established	 by	 self‐assembly	 of	
hepatocytes,	 liver	sinusoidal	ECs,	and	mesenchymal	stem	cells	cultured	in	high	cellular	
density	(Fig.	13A	and	B).	The	metabolic	and	enzymatic	activity	and	substrate	conversion	
was	 described	 as	 well	 as	 the	 liver‐specific	 protein	 production	 and	 metabolism115.	
After	self‐assembly	 of	 the	 different	 cell	 types	 to	 a	 dense	 organoid,	 they	 could	 only	 be	
maintained	 in	 culture	 for	 a	maximum	 of	 72	 h	 due	 to	 increasing	 nutrient	 and	 oxygen	
deficiency	 leading	 to	 apoptosis	 and	 necrosis	 in	 the	 inner	 cell	 mass	 of	 the	 organoid.	
Acute	nutrient	 and	 oxygen	 deficiency	 could	 be	 circumvented	 by	 implementing	
the	organoids	 into	 a	 dynamic	 perfusion	 culture	 setup118.	 Combining	 the	 organoid	
technology	with	 the	mBioVaSc‐TERM®,	 the	 perfusion	 culture	within	 the	 vascularized	
scaffold	(Fig.	13D)	increased	organoid	culture	for	one	week.	However,	functional	analysis	
by	 HPLC	 of	 converted	 metabolites	 from	 the	 culture	 supernatant	 demonstrated	 that	
the	capacity	for	liver‐specific	enzymatic	conversion	of	the	cultured	organoids	was	only	on	















One	 strategy	was	 the	 transplantation	of	 a	drug	delivery	 system	releasing	 inhibitors	of	
proteins	limiting	muscle	mass.	Activin	A	and	Myostatin	are	negatively	regulating	skeletal	














increase	 in	 secretion	 despite	 similar	 cell	 number	 might	 be	 the	 perfusion	 culture.	
In	contrast	to	static	culture,	within	the	bioreactor	there	was	a	steady	medium	turnover,	
thereby	 constantly	 reducing	 the	 local	 drug	 concentration	 presumably	 avoiding	 a	
saturation	but	facilitating	constant	release.		
Furthermore,	it	was	demonstrated	that	the	secreted	drugs	did	not	only	diffuse	into	the	
surrounding	 reactor	 compartment	 but	 were	 distributed	 throughout	 the	 bioreactor	
system.	Therefore,	the	secreted	drugs	must	have	passed	the	endothelial	barrier	to	reach	
into	the	intravascular	compartment	and	subsequently	being	distributed	throughout	the	








Beyond	 secretion	 of	 the	 proteins,	 their	 biological	 activity	was	demonstrated	 as	 this	 is	
critical	 to	 elicit	 a	 therapeutic	 effect.	 Utilizing	 the	 effect	 of	 Activin	A	 and	Myostatin	 on	
inhibition	of	cell	proliferation	of	MPC‐11	cells122,	the	biological	activity	was	demonstrated	
by	 applying	 the	 secretome	of	 the	 genetically	modified	CHO	 cells	 onto	MPC‐11	 cells	 to	
determine	 MPC‐11	 proliferation	 kinetics	 dependent	 on	 the	 applied	 supernatant	
concentration	 (Fig.	 14B).	 The	 different	 biological	 efficiency	 of	 both	 proteins	 was	
represented	by	the	distinct	inhibitory	effect	on	the	proliferation	kinetics	in	MPC‐11	cells.	




In	 summary,	 not	 only	 cellular	 survival	 and	 secretion	 was	 demonstrated	 but	 also	 the	
biological	 activity	 of	 the	 secretome	 proving	 the	 concept	 of	 the	 mBioVaSc‐TERM®	 to	








of	 the	 mBioVaSc‐TERM®.	 In	 contrast	 to	 constitutive	 secretion,	 numerous	 metabolic	
diseases	demand	a	highly	regulated	release	of	factors.	A	constant	secretion	as	with	the	
constitutive	producing	 cells	 generated	above	might	have	disadvantageous	 side	 effects.	
Therefore,	the	drug	secretion	has	to	be	tightly	regulated	in	a	dose	dependent	manner	by	
feedback	mechanisms.	However,	 the	 implementation	of	 all	 the	 required	 feedback	 loop	
mechanisms	by	genetic	engineering	is	highly	laborious.		
To	 demonstrate	 the	 capacity	 of	 the	 mBioVaSc‐TERM®	 to	 maintain	 naturally	 drug	











and	 function.	 Furthermore,	 the	 employed	 islets	 were	 immature	 when	 isolated	 upon	
insulin	 secretory	 activity230,	 as	 indicated	 by	 the	 immunohistological	 staining	 hardly	
verifying	insulin+	staining	on	the	cultured	NICCs	(Fig.	15D).	Nevertheless,	the	islets	were	
viable	in	the	luminal	culture	within	the	mBioVaSc‐TERM®	(Fig.	15B)	as	well	as	secretion	
of	 insulin	 was	 demonstrated	 in	 the	 co‐culture	 setup.	 However,	 insulin	 secretion	 was	





a	 trend	 in	 increased	 insulin	 secretion.	Though,	 no	 impact	 of	ECs	on	 increasing	 insulin	
secretion	is	known,	it	was	likely	that	the	raised	insulin	levels	were	due	to	elevated	NICC	
viability	by	directly	co‐culturing	ECs	additional	to	the	revascularized	structures.		











cell	 technology.	 Based	 on	 the	 herein	 established	 concept,	 the	 mBioVaSc‐TERM®	 will	
provide	the	framework	for	a	3D	co‐culture	system	of	human	iPS	cells	differentiated	into	











NICCs.	 Exploiting	 the	 capacity	 of	 ECs	 for	 angiogenesis198,	 combined	 with	 the	
implementation	of	sprouting	and	tube	forming	EC‐spheroids	co‐cultured	with	tissue‐like	
organoids102,103,	 intraluminal	 vascularization	 might	 be	 achieved.	 Inner‐luminal	
vascularization	 interconnected	 to	 the	 capillary	 branches	 embedded	 inside	 the	 luminal	
ECM	 of	 the	 mBioVaSc‐TERM®	 would	 establish	 a	 fully	 pervading	 vessel	 network	
throughout	 the	 luminal	 compartment.	 Thereby,	 promoting	 vascularization	 inside	 the	
luminal	 cavity	 beyond	 revascularization	 of	 the	 scaffold	 vasculature,	 might	 enable	 full	
thickness	tissue	graft	generation.		
Beyond,	 by	 improving	 the	 venous	 return	with	 establishing	 a	 colloid	 osmotic	 gradient	
between	 intra‐	 and	 extravascular	 space	 and	utilizing	 the	distinct	 afferent	 and	 efferent	
vessel	system,	drugs	could	be	delivered	via	the	simulated	blood	stream	to	a	generated	
tissue	 within	 the	 luminal	 compartment	 of	 the	 mBioVaSc‐TERM®.	 The	 returned	
compounds	might	 be	 analyzed	 upon	 the	 capacity	 to	 pass	 the	 endothelial	 barrier	 and	
tissue‐specific	 drug	metabolism	 as	 well	 as	 the	 tissue	 itself	 can	 be	 analyzed	 upon	 the	
metabolic	pathways	induced	by	exposition	to	a	certain	drug	in	an	in	vivo‐like	situation.	
This	technology	might	facilitate	basic	research	on	organ	function	and	metabolic	pathways	
as	 well	 as	 give	 further	 insight	 on	 disease	 patterns	 including	 vascular	 diseases.	
Constituting	 organ‐specific	 tissue	 pervaded	 by	 endothelialized	 vessels,	 the	mBioVaSc‐
TERM®	 might	 function	 as	 an	 in	 vivo‐like	 test	 system	 utilized	 for	 drug	 screening,	
metabolism	and	toxicity	studies	as	well	as	a	cancer	model	enabling	the	examination	of	










In	 summary,	 to	 demonstrate	 the	 capacity	 of	 the	 mBioVaSc‐TERM®	 as	 a	 platform	
technology	 for	 vascularized	 tissue	 graft	 generation,	 multicellular	 organoids,	
genetically	modified	 cells	 for	 drug	 release	 or	 naturally	 hormone	 secreting	 cell	 cluster	
were	 maintained	 viable	 and	 functional	 in	 a	 co‐culture	 setup.	 The	 biologically	 active	
secreted	proteins	were	determined	 to	be	distributed	 throughout	 the	whole	bioreactor	





The	mBioVaSc‐TERM®	was	 demonstrated	 to	 be	 biocompatible	 and	 haemocompatible,	
to	enable	 revascularization	 and	 facilitate	 physiological	 vascular	 perfusion,	 and	 to	
maintain	tissue‐like	co‐culture.		
Next,	 the	 translation	toward	clinical	applicability	was	evaluated,	demonstrating	 in	vivo	
proof	of	 concept	whether	 the	mBioVaSc‐TERM®	 is	 suitable	as	 scaffold	 for	 tissue	graft	
generation	and	further	as	Advanced	Therapy	Medicinal	Product	(ATMP).	To	determine	
the	capacity	as	human	cell	therapy	application,	immunodeficient	small	animal	models	are	
most	 suitable	 to	 not	 compromise	 the	 proof	 of	 concept	 by	 heterologous	 immune	
rejection156.	 In	 particular,	 the	 mBioVaSc‐TERM®	 was	 revascularized	 with	 hdmECs	



























and	 implanted	 in	 nude	 rats.	 After	 anastomosis	 of	 the	mBioVaSc‐TERM®	 onto	 the	 rat	
vasculature,	 the	 mBioVaSc‐TERM®	 was	 perfused	 by	 an	 unobstructed	 unidirectional	
blood	flow	as	a	part	of	the	animal’s	blood	circulation.	With	the	mBioVaSc‐TERM®	directly	
anastomosed	 to	 the	 blood	 circulation,	 an	 immediate	 foreign	 body	 reaction	 was	 not	
expected	due	to	the	utilization	of	immunodeficient	rat	and	the	well	described	successful	





The	 in	vitro	 tested	vascular	 tightness	and	haemocompatibility	of	 the	 reendothelialized	
vascular	 tree	 were	 confirmed	 in	 vivo,	 preventing	 leakage	 and	 acute	 thrombosis.	
Furthermore,	the	rats	with	implanted	grafts	showed	no	signs	of	rejection	nor	intolerance,	














signs	 of	 foreign	 body	 reaction	 nor	 graft	 remodeling	 or	 turnover	 within	 the	 first	
3	days	(Fig.	18A).		
Even	 after	 7	 days	 in	vivo,	 the	 mBioVaSc‐TERM®	 was	 only	 faintly	 covered	 by	 loose	
connective	tissue	and	the	vascular	function	seemingly	unimpaired	(Fig.	18B).	As	this	did	




30	days	post	 implantation,	 the	scaffold	was	entirely	encapsulated	and	adherent	 to	 the	
surrounding	tissue	but	still	easily	dissected	therefrom	(Fig.	18C).	This	was	in	 line	with	
peritoneal	 healing,	 depicting	 critical	 progression	 of	 adhesion	 formation	 after	 seven	
days237.		
Beyond	 this	 time	 frame,	 when	 implanted	 for	 120	 days	 in	 vivo,	 the	 graft	 was	




In	fact,	 connective	 tissue	overgrowth	was	utilized	 therein	enabling	vascular	sprouts	 to	
surround	 and	 infiltrate	 the	 transplant.	 Thereby,	 a	 prevascularization	 of	 an	 originally	
avascular	biomaterial	was	achieved.	This	strategy	for	TE	requires	an	implantation	in	vivo	








Next,	 the	 prevascularized	 graft	 is	 finally	 implanted	 again.	 Due	 to	 the	 beforehand	
established	prevascularization,	the	connection	of	the	vascular	structures	within	the	graft	
and	the	host	vasculature	will	now	occur	quicker	enabling	nutrient	supply	and	minimized	
graft	 necrosis.	 Nevertheless,	 two	 surgeries	 are	 necessary	 and	 after	 explantation	 and	
reimplantation	 the	 ingrown	vessels	do	not	provide	a	connection	 to	 the	circulation	any	
more,	which	has	to	be	reestablished	by	sprouting	anew.		
Comparing	 the	 established	 mBioVaSc‐TERM®	 with	 other	 engineered	 scaffolds235,	




However,	 the	 exploitation	 of	 biomaterial	 encapsulation	 indicates	 that	 the	 in	 vivo	
overgrowth	of	 the	mBioVaSc‐TERM®	might	 be	 advantageous	 for	 long‐term	 functional	
tissue	integration.	In	contrast,	sealing	the	mBioVaSc‐TERM®	off	the	surrounding	tissue	









fibrinolytic	 activity	 protecting	 against	 adhesions	 and	 thromboses243.	 Upon	 injury	 or	
inflammation	 a	 regeneration	 cascade	 is	 triggered	 and	 peritoneal	 healing	 is	 normally	
completed	within	7	–	10	days244	by	differentiation	of	underlying	mesenchymal	 cells245.	
Otherwise,	 if	 regeneration	 is	 impeded,	 scarring	 occurs	 inducing	 peritoneal	 adhesion	
formation245.		
Furthermore,	due	to	surgical	trauma	such	as	tissue	desiccation,	irradiation,	hemorrhage,	
ischemia,	 and	 reactions	 to	 foreign	materials	 introduced	 during	 the	 procedure	 such	 as	







surgery	 is	 93	 %.	 However,	 in	 most	 cases,	 they	 do	 not	 cause	 severe	 symptoms.	
Nevertheless,	 they	 might	 progressively	 become	 larger	 and	 tighter	 provoking	 chronic	
abdominal	 pain	 to	 the	 point	 of	 intestinal	 obstruction	 even	 years	 after	 the	 surgery	
requiring	a	second	operation	to	break	the	adhesion247.		
In	 case	 of	 the	 mBioVaSc‐TERM®,	 considering	 the	 1.5	–	2	hours	 surgical	 implantation	
procedure	for	anastomosis	and	implantation	of	the	mBioVaSc‐TERM®	it	was	very	likely	
for	 a	 surgical	 intervention‐caused	 inflammation	 to	 occur.	 Furthermore,	
during	decellularization	 all	 cells	 including	 the	 naturally	 present	 mesothelial	 cells	
secreting	the	protective	surfactant	were	removed.	Thereby,	upon	implantation,	the	graft	
was	 unprotected	 with	 the	 exposed	 bare	 ECM	 of	 the	 mBioVaSc‐TERM®	 incapable	 of	
regeneration,	most	 likely	 triggering	peritoneal	 scarring	 in	 consequence	 of	 the	missing	
surfactant	 and	 surfactant	 producing	 cells.	 Consequently,	 excessive	 ECM	 is	 likely	 to	 be	
deposited	 successively	 establishing	 a	 fibrous	 bridge	 between	 tissues244.	 Thereby,	
the	scaffold	was	exposed	to	matrix	turnover,	scarring	and	thus	fibrous	tissue	deposition	
anchoring	 the	 graft	 to	 its	 abdominal	 environment248	 and	 ultimately	 integrated	 or	
disintegrated	dependent	on	the	biocompatibility	and	vitality	of	the	graft	tissue.		
For	 the	 mBioVaSc‐TERM®,	 adhesion,	 anchorage,	 and	 incorporation	 are	 not	 generally	
disadvantageous.	In	contrast,	the	overgrowth	of	implanted	biomaterials	with	collagenous	
tissue	 and	 cell	 infiltration	was	 exploited	 to	 create	 living	 autologous	 tissue249	with	 the	
mechanical	properties	and	functions	of	the	primarily	implanted	biomaterial250.	However,	
further	 analysis	 has	 to	 demonstrate	 whether	 the	 mBioVaSc‐TERM®	 was	 integrated	
within	the	tissue	with	sprouting	vessels	or	whether	the	surrounding	tissue	was	fibrotic	












establish	 prevascularization,	 there	 is	 a	 high	 risk	 for	 peritoneal	 adhesions	 causing	



















tissues	 depicted	 the	 clinically	 most	 successful	 adhesion	 barriers	 in	 current	 clinical	
applications253.		
Hence,	to	diminish	the	prevalent	hazard	a	barrier	to	shield	the	implant	was	employed	that	
was	 also	 supposed	 to	 enable	 easier	 graft	 recovery	 and	 subsequent	 analysis.	 The	
GORE®	DUALMESH®	biomaterial	was	used	to	promote	host	tissue	incorporation	on	one	
side	 while	 minimizing	 tissue	 attachment	 on	 the	 other254.	 However,	 employing	 the	
GORE®	DUALMESH®	biomaterial	did	not	reduce	tissue	encapsulation.	In	contrast,	when	












without	 signs	 of	 adverse	 reactions	 by	 the	 animal.	 In	 both	 cases,	 similar	mechanisms,	
chemical	mediators,	matrix	metalloproteinases,	and	macrophages	present	in	blood	and	




occurred	 improving	 graft	 integration.	 The	 immediate	 anastomosis	 establishing	 blood	
circulation	 throughout	 the	 graft	 might	 facilitate	 short‐term	 survival	 of	 the	 implanted	
tissue.	However,	for	long‐term	tissue	integration,	additional	sprouting	and	expansion	of	




host	might	 be	more	 promising	 in	minimizing	 the	 risk	 for	 pathologic	 adhesions	 while	
preserving	 the	 mBioVaSc‐TERM®	 from	 degradation	 but	 allowing	 tissue	 integration.	




Instead	 of	 solid	 barriers,	 fluids	 and	 gels	 are	 described	 as	 absorbable	 surfactant	
lubricants257	 to	 reduce	 the	 incidence	of	 adhesions	until	 the	natural	 barrier	 of	 affected	
areas	 is	 regenerated	 after	 a	 surgical	 intervention.	 Embedded	 in	 hydrogels	 or	 applied	
independently,	 medication	 was	 developed	 targeting	 the	 molecular	 mechanisms	 of	 to	
significantly	 decrease	 adhesion	 formation258.	 Hellebrekers	 et	 al.	 reviewed	 fibrinolytic	
agents	 aiming	 for	 the	 prevention	 of	 the	 onset	 of	 adhesion	 or	 the	 immediate	 lysis	 of	
excessive	ECM	deposition	counteracting	developing	fibrous	bridge	formation.		
A	 TE	 approach	 suggested	 the	 implementation	 of	 mesothelial	 cells253	 on	 the	 scaffold	






visceral	 mesothelial	 layer	 on	 the	 mBioVaSc‐TERM®,	 as	 present	 on	 internal	 organs	
reducing	 the	 incidence	 of	 peritoneal	 adhesion.	 Regarding	 clinical	 application,	
autologous	cells	 implemented	 potentially	 provoke	 immune	 reactions.	 However,	
autologous	mesothelial	 cell	 isolation	 requires	 the	 determination	 of	 suitable	 sites	 for	




of	 mesothelial	 cells	 from	 iPS	 cells	 might	 be	 a	 potential	 alternative,	 however,	
similarly	laborious	and	requires	proof	of	safety	of	the	iPS	cells259.		
Besides	the	implementation	of	cells	facilitating	surface	functionalization,	the	capability	of	
functionalizing	 the	 mBioVaSc‐TERM®	 ECM	 with	 the	 respective	 proteins	 could	 be	
determined	alternatively.		
In	 summary,	 without	 a	 mesh	 envelope	 constituting	 a	 definite	 barrier,	 the	 graft	 was	
integrated	 into	 the	 surrounding	 tissue,	while	 the	mesh	enveloped	graft	was	degraded.	




















responds	 dynamically	 to	 the	 needs	 of	 the	 surrounding	 tissue	 for	 nutrients	 and	




established	 in	 vitro,	 angiogenetic	 vascular	 remodeling	 and	 expansion262	 was	 not	
investigated	in	particular.		
With	 vascular	 regression	 observed	 in	 vivo,	 a	 strategy	 to	 circumvent	 endothelial	
degradation	might	 be	 the	 implementation	 of	 co‐cultured	 cells	 or	 an	 organ‐like	 tissue	




well	 as	 vascular	 regression	 frequently	 occur	 during	physiological	 processes	 as	wound	
healing	and	inflammation264.	Vascular	remodeling	is	mainly	triggered	by	VEGF.	Simplified,	
an	 excess	 of	 VEGF	 results	 in	 angiogenic	 sprouting,	 while	 a	 lack	 leads	 to	 regression	
initiated	by	apoptosis	of	ECs.	The	latter	is	explained	by	anti‐apoptotic	characteristics	of	
VEGF	 promoting	 cell	 survival	 while	 inhibiting	 caspase	 activation265.	 ECs	 express	
endogenous	 VEGF,	 however,	 only	 to	 maintain	 expression	 of	 VEGF	 receptor	 and	 cell	
adhesion	molecules266.		
The	 first	 sign	 for	 vascular	 regression	 is	 stagnancy	 of	 the	 blood	 flow	 in	 the	 respective	
vessels.	Subsequently,	the	vascular	wall	components	become	gradually	removed:	the	ECs	
undergo	 apoptosis267,	 whereas	 the	 fate	 of	 the	 pericytes	 is	 controversially	 discussed	
whether	they	also	become	apoptotic	or	dedifferentiate	into	fibroblast	and	migrate	into	
the	connective	tissue264.	Finally,	residual	debris	of	coagulated	blood	and	apoptotic	cells	
gets	 cleared	 by	 phagocytosis268.	 An	 empty	 basement	 membrane	 is	 the	 only	 remnant	
remaining	 from	the	 former	vessel.	This	phenomenon	described,	explains	 the	observed	
gradual	long‐term	decline	of	the	mBioVaSc‐TERM®	vascularization	in	vivo.		
Without	 sufficient	 stimuli	 to	 sustain	 the	 vascularization	 of	 the	mBioVaSc‐TERM®	and	







Liver‐like	organoids	were	 implemented,	but	presumably	 too	 little	 to	 induce	a	relevant	
demand	 for	 vascular	 ingrowth	 countering	 the	 vascular	 regression.	 If	 the	 luminal	
compartment	would	be	filled	with	organoids,	an	established	full	thickness	tissue	might	
pose	 a	 high	 enough	 demand	 for	 vascular	 sprouting.	 Hypoxic	 cells	 express	 angiogenic	
molecules,	 such	 as	 VEGF,	 to	 stimulate	 the	 migration	 of	 endothelial	 precursors	 for	
vasculogenesis	and	thereby	reduce	the	oxygen	tension	towards	blood	vessels269.		





their	 tissue‐specific	 function	 in	 addition	 to	 VEGF	 release.	 Thereby,	 sustained	 vascular	
integrity	might	be	demonstrated	as	well	as	sustained	functionality	of	the	implanted	graft	
tissue.	Furthermore,	if	the	function	of	implemented	cells	or	tissue	is	vital	for	host	survival	




culture,	 the	 implementation	 of	 vascular	 spheroids102	 or	 vascular	 growth	 factors	 could	

















polymers	 provided	 a	 controlled	 release	 mathematically	 predictable	 upon	 dose	 and	
period.	Stimuli‐responsiveness	allowed	the	timely	and	spatially	specific	drug	release	from	
polymers271.	 However,	 polymers	 for	 drug	 delivery	 depict	 a	 single	 use	 application	 and	
require	subsequent	administration	when	consumed.	With	the	rising	prevalence	of	chronic	
disorders,	 however,	 the	 demand	 for	 sustainable	 devices	 continually	 rises.	
Despite	pharmacological	advancements	upon	absorption,	distribution,	metabolism,	and	
excretion	(ADME)	 of	 pharmaceutical	 compounds	 and	 promising	 drug	 delivery	









Liver‐like	 organoid	 culture	 within	 the	 mBioVaSc‐TERM®	 lumen	 indicated	 the	
maintenance	of	in	vivo	tissue	culture,	though,	only	in	short‐term.	Beyond	7	days	in	vivo,	


















Advancing	 from	 the	 identified	 drawbacks,	 improving	 long	 term	 stability	 in	 vivo,	 and	




labelled	 cells	 might	 be	 cultured	 inside	 the	 mBioVaSc‐TERM®	 lumen,	 enabling	 cell	
tracking	to	determine	whether	the	cells	migrate	outside	the	graft.	Secretion	of	fluorescent	
proteins	or	fluorescently	labeled	proteins	would	allow	for	tracking	the	distribution	of	the	
cell	 secretome,	 proving	 applicability	 as	 drug	 delivery	 system.	 Both	 approaches	 are	
feasible	 as	 the	 in‐house	 available	 In	Vivo	 Imaging	 System	 (IVIS)	 enables	 non‐invasive	
imaging	and	monitoring.		
Furthermore,	 demonstrating	 drug	 secretion	 and	 distribution	 in	 vivo,	 besides	 cells	
secreting	fluorescent	proteins	a	variety	of	available	cell	sources	might	be	implemented	
demonstrating	 functional	 and	 bioactive	 proof	 of	 concept.	 Therefore	 the	 generated	
Activin	A‐	or	Myostatin‐secreting	CHO	cells,	the	liver‐like	organoids	might	be	examined	
upon	human	albumin	secretion,	or	 factor	VIII	secreting	cells	generated	 in	a	project	 for	
hemophilia	 A	 treatment.	 Either	 cell	 type	 is	 accessible	 for	 implementation	 in	 the	
mBioVaSc‐TERM®	with	its	secretome	specifically	detectable	from	blood	samples	taken	
after	implantation	and	verified	by	commonly	available	ELISA	or	western	blot	techniques.	
Examination	of	blood	 samples	enables	 the	 functional	proof	 concept	without	end	point	
analysis	 and	 thereby	 an	 extensive	 time	 course	 of	 steady	 analysis	 of	 availability	 of	 the	








In	 this	 thesis,	 a	 rat	 jejunal	 segment	was	 identified	as	 suitable	 scaffold	 to	 function	as	a	
vascularized	platform	technology	for	TE	and	as	drug	delivery	system.	The	miniaturized	
rat‐derived	version	of	the	BioVaSc‐TERM®	provided	similar	properties	as	the	porcine‐
derived	 scaffold,	 including	 an	 innate	 vascular	 network	 embedded	 in	 a	 natural	 ECM	
providing	 supply	 for	 a	 3D	 cell	 co‐culture	 environment.	 Despite	 the	 smaller	 scale,	






























Despite	 highlighting	 the	 arteriovenous	 circulation	 within	 the	 scaffold	 to	 supply	
implemented	co‐cultures	as	well	as	the	feasibility	of	the	anastomosis	to	enable	immediate	
supply	 in	 vivo,	 the	 effective	 advantage	 of	 both	 still	 has	 to	 be	 demonstrated	 for	 the	
mBioVaSc‐TERM®.	
Furthermore,	 improvement	 of	 vascular	 stability	 and	 the	 advancement	 of	 the	 3D	 co‐
culture	within	the	intraluminal	compartment	has	to	be	further	pursued	to	establish	and	
sustain	a	functional	full	thickness,	fully	vascularized	organ‐like	tissue	graft.	
To	be	considered	for	 future	ATMP	development,	 the	depicted	drawbacks,	 in	particular	






Nevertheless,	due	 to	 the	promising	proof	of	 concept	and	 the	displayed	capacity	of	 the	






development	 with	 the	 possibility	 for	 preclinical	 small	 animal	 model	 implantations	
granting	faster	results	due	to	its	smaller	size,	lower	cell	amount	necessary	for	confluent	
culture	 and	 easier	 handling.	 The	 miniaturized	 biologically	 vascularized	 scaffold	 as	
platform	technology	 for	 the	generation	of	 functional	 tissue	grafts	or	 the	application	as	
drug	delivery	system	could	serve	as	a	powerful	tool	for	TERM	substituting	for	a	loss	of	
















protocols	 for	 isolation,	 characterization,	 culture277,	 and	 therapeutic	 application278	 are	
described.	 Moreover,	 the	 larger	 vessels	 within	 the	 mBioVaSc‐TERM®	 lack	 SMCs	
promoting	vascular	sprouting,	angiogenesis,	maturation,	functionality,	and	stability277	as	
well	 as	 pericytes	 contributing	 to	 vessel	 maturity,	 structure,	 and	 stability279.	 Beyond,	
embryonic	stem	and	iPS67	cells	depict	a	potentially	infinite	source	of	autologous	cells	for	
regeneration	 pushing	 towards	 clinical	 application30.	 Furthermore,	 a	 differentiation	





ECM,	 the	 capillary	 network	 is	 aimed	 to	 be	 expanded	 to	 sprout	 into	 the	 intraluminal	
compartment	to	fully	pervade	a	full	thickness	tissue.	Intraluminal	tissue	vascularization	




The	 achieved	 success	 in	 decellularization	 and	 revascularization	 of	 a	 vastly	 branched	
vascular	 network	 encourages	 the	 attempt	 to	 generate	 custom‐tailored	 vessels,	 e.g.	 for	
bypass	 surgeries.	 Certainly,	 the	 complexity	 of	 the	 branched	 capillary	 bed	 is	 irrelevant	
when	 generating	 a	 single	 straight	 tubular	 structure,	 however,	 the	 seemingly	












desired	 implantation	 site.	 Nevertheless,	 with	 the	 prevalent	 experience	 on	 de‐	 and	
recellularization	of	vascular	structures	and	the	great	 interdisciplinary	team	of	medical,	




Employing	 immunodeficient	 RNU	 rats284	 for	 initial	 implantation	 studies	 enabled	 the	
evaluation	of	the	proof	of	concept	of	the	clinical	applicability	of	the	mBioVaSc‐TERM®.	
Considering	 further	 studies,	 the	 use	 of	 autologous	 cells	 circumvents	 the	 need	 for	 the	
recipient	to	be	immune‐deprived.		
	
In	 case	 of	 a	 loss	 of	 function	 or	 tissue	 replacement	with	 no	 cells	 or	 not	 enough	 viable	
autologous	cells	extractable	for	sufficient	expansion	and	graft	establishment	an	allo‐	or	
xenogenic	source	will	be	inevitable.	Thereby,	immunosuppression	becomes	mandatory	to	
protect	 the	 graft	 from	 the	 host	 immune	 response	 even	 though	 the	 application	 of	
immunosuppressants	is	adverse	due	to	its	side	effects285.	In	this	regard,	the	feasibility	of	
the	 implementation	 of	 localized	 immunosuppression	 was	 discussed	 lately	 to	 avoid	
systemic	effects	while	protecting	the	graft286.	With	yet	only	preliminary	data	available,	




animal	 models	 and	 subsequently	 in	 large	 animals	 need	 to	 be	 feasible	 to	 prove	
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